: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription

Articles published in Lung Cancer
Retrieve available abstracts of 1082 articles:
HTML format

Single Articles

July 2021

KOZONO DE, Stinchcombe TE, Salama JK, Bogart J, et al
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
Lung Cancer. 2021;159:56-65.
PubMed Abstract available

ZHAO M, Wu J, Deng J, Wang T, et al
Proposal for Rib invasion as an independent T descriptor for non-small cell lung cancer: A propensity-score matching analysis.
Lung Cancer. 2021;159:27-33.
PubMed Abstract available

RAD HS, Rad HS, Shiravand Y, Radfar P, et al
The Pandora's box of novel technologies that may revolutionize lung cancer.
Lung Cancer. 2021;159:34-41.
PubMed Abstract available

VAN BREESCHOTEN J, Ismail R, Smit H, Schuurbiers O, et al
An invisible group of COVID-19 victims; impact on Dutch lung cancer care.
Lung Cancer. 2021 Jul 19. pii: S0169-5002(21)00476.
PubMed

SHEN Y, Zhang Y, Guo Y, Li W, et al
Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis.
Lung Cancer. 2021;159:111-116.
PubMed Abstract available

KOCHER F, Tymoszuk P, Amann A, Sprung S, et al
Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.
Lung Cancer. 2021;159:84-95.
PubMed Abstract available

USUZAKI T, Takahashi K, Umemiya K, Ishikuro M, et al
Augmentation method for convolutional neural network that improves prediction performance in the task of classifying primary lung cancer and lung metastasis using CT images.
Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00468.
PubMed

FUNG AS, Graham DM, Chen EX, Stockley TL, et al
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
Lung Cancer. 2021;157:21-29.
PubMed Abstract available

POPAT S, Brustugun OT, Cadranel J, Felip E, et al
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Lung Cancer. 2021;157:9-16.
PubMed Abstract available

GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
Lung Cancer. 2021;157:167.
PubMed

CLERMIDY H, Maury JM, Collaud S, Drevet G, et al
Lymph Node Dissection in Thymoma: Is it worth it?
Lung Cancer. 2021;157:156-162.
PubMed Abstract available

XIE XJ, Liu SY, Chen JY, Zhao Y, et al
Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
Lung Cancer. 2021;157:30-39.
PubMed Abstract available

TALCOTT WJ, Miccio JA, Park HS, White AA, et al
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
Lung Cancer. 2021;157:17-20.
PubMed Abstract available

ZHU VW, Zhao JJ, Gao Y, Syn NL, et al
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Lung Cancer. 2021;157:147-155.
PubMed Abstract available

LESIRE B, Durieux V, Grigoriu B, Girard N, et al
Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.
Lung Cancer. 2021;157:131-146.
PubMed Abstract available

SUGIMOTO A, Umemura S, Miyoshi T, Nakai T, et al
High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
Lung Cancer. 2021;157:1-8.
PubMed Abstract available

YANG Y, Ran J, Wang Y, Zhou Z, et al
Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases.
Lung Cancer. 2021;157:116-123.
PubMed Abstract available

PASSIGLIA F, Leone G, Olmetto E, Delcuratolo MD, et al
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.
Lung Cancer. 2021;157:85-91.
PubMed Abstract available

BASSE C, Daniel C, Livartowski A, Beaucaire-Danel S, et al
Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
Lung Cancer. 2021;157:79-84.
PubMed Abstract available

CHINTALA NK, Restle D, Quach H, Saini J, et al
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
Lung Cancer. 2021;157:48-59.
PubMed Abstract available

CERESOLI GL, Ghirardelli P, Franceschini D, Scorsetti M, et al
A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy".
Lung Cancer. 2021;157:165-166.
PubMed

BARSKY AR, Yegya-Raman N, Katz SI, Simone CB 2nd, et al
Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy.
Lung Cancer. 2021;157:163-164.
PubMed

June 2021

SU PL, Tsai JS, Yang SC, Wu YL, et al
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.
Lung Cancer. 2021;158:137-145.
PubMed Abstract available

WANG Z, Zhao J, Ma Z, Cui J, et al
Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268].
Lung Cancer. 2021 Jun 11. pii: S0169-5002(21)00426.
PubMed

BORG M, Wen SWC, Nederby L, Hansen TF, et al
Performance of the EarlyCDT(R) Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
Lung Cancer. 2021;158:85-90.
PubMed Abstract available

QI M, Bian D, Zhang J, Zhu X, et al
The modification of T description according to visceral pleural invasion and tumor size from 3.1cm to 4.0cm in non-small cell lung cancer: A retrospective analysis based on the SEER database.
Lung Cancer. 2021;158:47-54.
PubMed Abstract available

JOSHI K, Muhith A, Obeid M, Milner-Watts C, et al
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
Lung Cancer. 2021;156:147-150.
PubMed Abstract available

GACHECHILADZE M, Uberall I, Skanderova D, Matchavariani J, et al
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Lung Cancer. 2021;156:129-135.
PubMed Abstract available

LAROSE F, Quigley N, Lacasse Y, Martel S, et al
Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
Lung Cancer. 2021;156:151-156.
PubMed Abstract available

PRIETO M, Chassagnon G, Lupo A, Charpentier MC, et al
Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.
Lung Cancer. 2021;156:117-121.
PubMed Abstract available

SOLDATH P, Binderup T, Kjaer A, Federspiel B, et al
Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients.
Lung Cancer. 2021;156:109-116.
PubMed Abstract available

LAU SCM, Poletes C, Le LW, Mackay KM, et al
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
Lung Cancer. 2021;156:76-81.
PubMed Abstract available

NAKASUKA T, Ohashi K, Watanabe H, Kubo T, et al
A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
Lung Cancer. 2021;156:1-4.
PubMed Abstract available

May 2021

KIM HW, Kim JS, Lee SH
Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
Lung Cancer. 2021;158:107-114.
PubMed Abstract available

SATO T, Shimada Y, Mimae T, Tsutani Y, et al
The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.
Lung Cancer. 2021;158:9-14.
PubMed Abstract available

HE LN, Fu S, Zhang X, Hu Q, et al
Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
Lung Cancer. 2021;158:1-8.
PubMed Abstract available

LAVOLE A, Mazieres J, Schneider S, Brosseau S, et al
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
Lung Cancer. 2021;158:146-150.
PubMed Abstract available

DI STASIO GD, Travascio L, Colandrea M, Spaggiari L, et al
Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
Lung Cancer. 2021;158:40-46.
PubMed Abstract available

GOKER E, Altwairgi A, Al-Omair A, Tfayli A, et al
Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations.
Lung Cancer. 2021;158:60-73.
PubMed Abstract available

LIU R, Ota K, Iwama E, Yoneshima Y, et al
Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
Lung Cancer. 2021 May 25. pii: S0169-5002(21)00403.
PubMed Abstract available

SPIRA AI, Tu H, Aggarwal S, Hsu H, et al
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Lung Cancer. 2021;159:1-9.
PubMed Abstract available

OSTI MF, Agolli L, Valeriani M, Reverberi C, et al
Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].
Lung Cancer. 2021 May 21. pii: S0169-5002(21)00187.
PubMed

DUVERGE L, Bondiau PY, Claude L, Supiot S, et al
Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
Lung Cancer. 2021 May 15. pii: S0169-5002(21)00195.
PubMed Abstract available

PROVENCIO M, Mazarico Gallego JM, Calles A, Antonanzas M, et al
Lung cancer patients with COVID-19 in Spain: GRAVID study.
Lung Cancer. 2021 May 14. pii: S0169-5002(21)00193.
PubMed Abstract available

WISLEZ M, Domblides C, Greillier L, Mazieres J, et al
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Lung Cancer. 2021 May 13. pii: S0169-5002(21)00192.
PubMed Abstract available

PILLERON S, Maringe C, Charvat H, Atkinson J, et al
Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.
Lung Cancer. 2021 May 13. pii: S0169-5002(21)00194.
PubMed Abstract available

ROGASCH JMM, Frost N, Bluemel S, Michaels L, et al
FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
Lung Cancer. 2021 May 7. pii: S0169-5002(21)00171.
PubMed Abstract available

LEI H, Yang Y, Zhou W, Zhang M, et al
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
Lung Cancer. 2021 May 5. pii: S0169-5002(21)00170.
PubMed Abstract available

WANG LL, Yu H, Wang HY, Liu T, et al
Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Lung Cancer. 2021 May 3. pii: S0169-5002(21)00168.
PubMed

OSAROGIAGBON RU
The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events.
Lung Cancer. 2021;155:191-192.
PubMed

HALMOS B, Burke T, Kalyvas C, Vandormael K, et al
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Lung Cancer. 2021;155:175-182.
PubMed Abstract available

SUMI T, Nakata H, Chiba H
Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment.
Lung Cancer. 2021;155:196-198.
PubMed

LUO Y, Wei J, Zhang J, Zeng L, et al
Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
Lung Cancer. 2021;155:170-174.
PubMed Abstract available

NOORDHOF AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
Lung Cancer. 2021;155:163-169.
PubMed Abstract available

VAN DE STADT EA, Yaqub M, Lammertsma AA, Poot AJ, et al
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using (18)F-afatinib PET/CT imaging.
Lung Cancer. 2021;155:156-162.
PubMed Abstract available

LV W, Wang Y, Zhou C, Yuan M, et al
Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study.
Lung Cancer. 2021;155:78-86.
PubMed Abstract available

ZHAO D, Hou F, Li M, Qi Y, et al
A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma.
Lung Cancer. 2021;155:193-195.
PubMed

MORENO-RUIZ P, Corvigno S, Te Grootenhuis NC, La Fleur L, et al
Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
Lung Cancer. 2021;155:10-19.
PubMed Abstract available

FOREST F, Casteillo F, Da Cruz V, Yvorel V, et al
Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Lung Cancer. 2021;155:1-9.
PubMed Abstract available

ARRIETA O, Salas AA, Cardona AF, Diaz-Garcia D, et al
Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.
Lung Cancer. 2021;155:183-190.
PubMed Abstract available

April 2021

DEBIEUVRE D, Juergens RA, Asselain B, Audigier-Valette C, et al
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Lung Cancer. 2021 Apr 30. pii: S0169-5002(21)00165.
PubMed Abstract available

CHEN N, Li Q, Wang S, Xiong M, et al
Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).
Lung Cancer. 2021;156:82-90.
PubMed Abstract available

NEWMAN NB, Osmundson EC
Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.
Lung Cancer. 2021 Apr 26. pii: S0169-5002(21)00161.
PubMed Abstract available

FROESCH P, Mark M, Rothschild SI, Li Q, et al
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Lung Cancer. 2021;156:91-99.
PubMed Abstract available

PALL G, Gautschi O
Advances in the treatment of RET-fusion-positive lung cancer.
Lung Cancer. 2021 Apr 24. pii: S0169-5002(21)00159.
PubMed Abstract available

KUZDZAL J, Trybalski L, Hauer L, Cmiel A, et al
Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study.
Lung Cancer. 2021 Apr 22. pii: S0169-5002(21)00160.
PubMed Abstract available

TAMMEMAGI MC, Darling GE, Schmidt H, Llovet D, et al
Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
Lung Cancer. 2021;156:31-40.
PubMed Abstract available

ZHANG CC, Hou RP, Xia WY, Zeng WQ, et al
Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study.
Lung Cancer. 2021;156:100-108.
PubMed Abstract available

HORIUCHI K, Sato T, Kuno T, Takagi H, et al
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
Lung Cancer. 2021;156:59-67.
PubMed Abstract available

BOGART JA, Wang X, Masters GA, Gao J, et al
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
Lung Cancer. 2021;156:68-71.
PubMed Abstract available

HSU CL, Tsai TH, Huang CK, Yang CY, et al
Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
Lung Cancer. 2021;156:50-58.
PubMed Abstract available

VON DER THUSEN JH, Dumoulin DW, Maat APWM, Wolf J, et al
ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype.
Lung Cancer. 2021;156:72-75.
PubMed Abstract available

MILLER HA, Yin X, Smith SA, Hu X, et al
Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
Lung Cancer. 2021;156:20-30.
PubMed Abstract available

ITO S, Asahina H, Honjo O, Tanaka H, et al
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Lung Cancer. 2021;156:12-19.
PubMed Abstract available

WATERHOUSE D, Lam J, Betts KA, Yin L, et al
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Lung Cancer. 2021;156:41-49.
PubMed Abstract available

SCHREUDER A, Mets OM, Schaefer-Prokop CM, Jacobs C, et al
Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
Lung Cancer. 2021;156:5-11.
PubMed Abstract available

VISSER MPJ, van Grimbergen I, Holters J, Barendregt WB, et al
Performance insights of endobronchial ultrasonography (EBUS) and mediastinoscopy for mediastinal lymph node staging in lung cancer.
Lung Cancer. 2021 Apr 7. pii: S0169-5002(21)00132.
PubMed Abstract available

YANG L, Zhao W, Zhu H, Li X, et al
PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
Lung Cancer. 2021;154:219-220.
PubMed

COSTA FA, Amano MT, Asprino PF, Pavlick DC, et al
Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.
Lung Cancer. 2021;154:146-150.
PubMed Abstract available

VOLCKMAR AL, Christopoulos P, Kirchner M, Allgauer M, et al
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
Lung Cancer. 2021;154:131-141.
PubMed Abstract available

XIONG A, Li C, Xu J, Yang X, et al
Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
Lung Cancer. 2021;154:124-130.
PubMed Abstract available

SHANG X, Li Z, Sun J, Zhao C, et al
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Lung Cancer. 2021;154:105-112.
PubMed Abstract available

WANG YL, Wu ZZ, Zhang HR, Chen DS, et al
Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
Lung Cancer. 2021;154:216-218.
PubMed

ZHANG C, Wang H
Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors.
Lung Cancer. 2021;154:221-223.
PubMed

PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Lung Cancer. 2021;154:92-98.
PubMed Abstract available

ZHANG C, Wang H
The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores.
Lung Cancer. 2021;154:214-215.
PubMed

WEISSFERDT A, Pataer A, Swisher SG, Heymach JV, et al
Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
Lung Cancer. 2021;154:76-83.
PubMed Abstract available

LI Z, Li F, Pan C, He Z, et al
Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma.
Lung Cancer. 2021;154:69-75.
PubMed Abstract available

COLLAUD S, Alnajdawi Y, Stork T, Plones T, et al
Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience.
Lung Cancer. 2021;154:23-28.
PubMed Abstract available

KATZ SI, Roshkovan L, Berger I, Friedberg JS, et al
Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
Lung Cancer. 2021;154:5-12.
PubMed Abstract available

PATHIPATI MP, Yohannan TK, Tian L, Hornbacker K, et al
Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.
Lung Cancer. 2021;154:186-194.
PubMed Abstract available

March 2021

BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
Lung Cancer. 2021;155:136-143.
PubMed Abstract available

FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
Lung Cancer. 2021;155:144-150.
PubMed Abstract available

EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
Lung Cancer. 2021;155:114-119.
PubMed Abstract available

TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
Lung Cancer. 2021;155:120-126.
PubMed Abstract available

EVERS J, de Jaeger K, Hendriks LEL, van der Sangen M, et al
Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
Lung Cancer. 2021;155:103-113.
PubMed Abstract available

TAO J, Jatoi A, Crawford J, Lam WWT, et al
Role of dietary carbohydrates on risk of lung cancer.
Lung Cancer. 2021;155:87-93.
PubMed Abstract available

YUN JK, Lee GD, Choi S, Kim HR, et al
The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis.
Lung Cancer. 2021;155:94-102.
PubMed Abstract available

PARK K, Chang GC, Curigliano G, Lim WT, et al
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
Lung Cancer. 2021;155:127-135.
PubMed Abstract available

AREDO JV, Purington N, Su L, Luo SJ, et al
Metabolomic profiling for second primary lung cancer: A pilot case-control study.
Lung Cancer. 2021;155:61-67.
PubMed Abstract available

DAMHUS CS, Quentin JG, Malmqvist J, Siersma V, et al
Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A longitudinal survey.
Lung Cancer. 2021;155:46-52.
PubMed Abstract available

YOH K, Seto T, Satouchi M, Nishio M, et al
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Lung Cancer. 2021;155:40-45.
PubMed Abstract available

LIU J, Itchins M, Nagrial A, Cooper WA, et al
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Lung Cancer. 2021;155:28-33.
PubMed Abstract available

WANG W, Xu C, Chen H, Jia J, et al
Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Lung Cancer. 2021;155:20-27.
PubMed Abstract available

GARCIA CAMPELO MR, Lin HM, Zhu Y, Perol M, et al
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+non-small cell lung cancer (ALTA-1L).
Lung Cancer. 2021;155:68-77.
PubMed Abstract available

HASSAN A, Latif MT, Soo CI, Faisal AH, et al
Corrigendum to "Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods" [Lung Cancer 113 (2017) 1-3].
Lung Cancer. 2021 Mar 4. pii: S0169-5002(21)00084.
PubMed

MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
Lung Cancer. 2021;155:151-155.
PubMed Abstract available

ATTILI I, Tarantino P, Passaro A, Stati V, et al
Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
Lung Cancer. 2021;154:151-160.
PubMed Abstract available

MORAES FY, Mansouri A, Dasgupta A, Ramotar M, et al
Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
Lung Cancer. 2021;155:34-39.
PubMed Abstract available

KUNIMASA K
A reply to "Cardiac dysfunction due to Osimertinib".
Lung Cancer. 2021;153:195.
PubMed

BOMMART S, Pujol JL, Coffy A, Daures JP, et al
Authors reply to letter to the editor by Dr Degens et al.
Lung Cancer. 2021;153:185.
PubMed

ANAND K
Cardiac dysfunction due to Osimertinib.
Lung Cancer. 2021;153:193-194.
PubMed

BABA K, Yoshida T, Shiotsuka M, Kobayashi O, et al
Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.
Lung Cancer. 2021;153:182-183.
PubMed

ARAUJO-FILHO JAB, Chang J, Mayoral M, Plodkowski AJ, et al
Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
Lung Cancer. 2021;153:158-164.
PubMed Abstract available

FUCHS V, Roisman L, Kian W, Daniel L, et al
The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
Lung Cancer. 2021;153:126-133.
PubMed Abstract available

LI R, Jiang L, Zhou X, Lu Y, et al
Pseudo-small cell transformation in EGFR-mutant adenocarcinoma.
Lung Cancer. 2021;153:120-125.
PubMed Abstract available

MASRORI P, Vaesen Bentein H, Raskin J, Montagna M, et al
Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
Lung Cancer. 2021;153:117-119.
PubMed Abstract available

ZHAI X, Wu Q, Zeng Z, Suo J, et al
OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
Lung Cancer. 2021;153:171-173.
PubMed

WANG B, Chen R, Wang C, Chen H, et al
PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
Lung Cancer. 2021;153:176-178.
PubMed

REN P, Luo N, Qi Y, Wu Y, et al
A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
Lung Cancer. 2021;153:179-181.
PubMed

DEVEAUX AE, Allen TA, Al Abo M, Qin X, et al
RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
Lung Cancer. 2021;153:90-98.
PubMed Abstract available

LIU Y, Gao GF, Minna JD, Williams NS, et al
Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.
Lung Cancer. 2021;153:73-80.
PubMed Abstract available

ZHOU F, Huang Y, Cai W, Li J, et al
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
Lung Cancer. 2021;153:66-72.
PubMed Abstract available

AMEMIYA R, Miyoshi T, Aokage K, Suzuki J, et al
Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
Lung Cancer. 2021;153:56-65.
PubMed Abstract available

CHIA PL, Parakh S, Russell P, Gan HK, et al
Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
Lung Cancer. 2021;153:35-41.
PubMed Abstract available

SUZUKI J, Aokage K, Neri S, Sakai T, et al
Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
Lung Cancer. 2021;153:1-10.
PubMed Abstract available

KUNIMASA K, Oka T, Hara S, Yamada N, et al
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
Lung Cancer. 2021;153:186-192.
PubMed Abstract available

February 2021

LIU L, Bai H, Seery S, Li S, et al
Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis.
Lung Cancer. 2021;158:74-84.
PubMed Abstract available

LIU G, Brenner H, Chen C, Christiani D, et al
A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?"
Lung Cancer. 2021 Feb 26. pii: S0169-5002(21)00079.
PubMed

WONG SK, Alex D, Bosdet I, Hughesman C, et al
MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
Lung Cancer. 2021;154:142-145.
PubMed Abstract available

CHENG Y, Mok TS, Zhou X, Lu S, et al
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Lung Cancer. 2021;154:176-185.
PubMed Abstract available

FOURDRAIN A, Epailly J, Blanchard C, Georges O, et al
Lymphatic drainage of lung cancer follows an intersegmental pathway within the visceral pleura.
Lung Cancer. 2021;154:118-123.
PubMed Abstract available

KOK PS, Lee K, Lord S, Yang JC, et al
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
Lung Cancer. 2021;154:113-117.
PubMed Abstract available

KERR KM, Bibeau F, Thunnissen E, Botling J, et al
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Lung Cancer. 2021;154:161-175.
PubMed Abstract available

MAO K, Liu F, Liu X, Khuri FR, et al
Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
Lung Cancer. 2021 Feb 19. pii: S0169-5002(21)00073.
PubMed

GARON EB, Aerts J, Kim JS, Muehlenbein CE, et al
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
Lung Cancer. 2021;155:53-60.
PubMed Abstract available

OHARA S, Suda K, Fujino T, Hamada A, et al
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.
Lung Cancer. 2021;154:84-91.
PubMed Abstract available

LIU F, Liu Y, Liu X, Mao K, et al
Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
Lung Cancer. 2021 Feb 18. pii: S0169-5002(21)00072.
PubMed

CHENG H, Zou Y, Shah CD, Fan N, et al
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
Lung Cancer. 2021;154:99-104.
PubMed Abstract available

AHMED Z, Kennedy K, Subramanian J
The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis.
Lung Cancer. 2021;154:62-68.
PubMed Abstract available

CHEN X, Muhammad KG, Madeeha C, Fu W, et al
Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection.
Lung Cancer. 2021 Feb 14. pii: S0169-5002(21)00065.
PubMed Abstract available

SEBASTIAN M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, et al
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Lung Cancer. 2021;154:51-61.
PubMed Abstract available

HENG WS, Pore M, Meijer C, Hiltermann TJN, et al
A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.
Lung Cancer. 2021;154:13-22.
PubMed Abstract available

SPAGGIARI L, Bertolaccini L, Facciolo F, Gallina FT, et al
A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
Lung Cancer. 2021;154:29-35.
PubMed Abstract available

LAMOTE K, Van den Heuvel MM
Where the nose is going to help the eye: Sniffing lung cancer.
Lung Cancer. 2021 Feb 10. pii: S0169-5002(21)00063.
PubMed

PALLARI E, Eriksson M, Billhult A, Billhult T, et al
Lung cancer research and its citation on clinical practice guidelines.
Lung Cancer. 2021;154:44-50.
PubMed Abstract available

WANG S, Chen H, Zhong J, Qin H, et al
Corrigendum to "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung" [Lung Cancer 135 (2019) 116-122].
Lung Cancer. 2021 Feb 2. pii: S0169-5002(21)00014.
PubMed

CAI C, Tang Y, Li Y, Chen Y, et al
Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Lung Cancer. 2021;152:104-108.
PubMed Abstract available

LI X, Liu J, Guo M, Cai H, et al
NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
Lung Cancer. 2021;152:202-204.
PubMed

LAZAREV S, Rosenzweig K, Samstein R, Salgado LR, et al
Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.
Lung Cancer. 2021;152:157-164.
PubMed Abstract available

ZHAO G, Chen L, Xiao M, Yang S, et al
Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
Lung Cancer. 2021;152:189-192.
PubMed

MARCUSE F, Hochstenbag M, Hoeijmakers JGJ, Hamid MA, et al
Subclinical myasthenia gravis in thymomas.
Lung Cancer. 2021;152:143-148.
PubMed Abstract available

HIROSE T, Ikegami M, Endo M, Matsumoto Y, et al
Extensive functional evaluation of exon 20 insertion mutations of EGFR.
Lung Cancer. 2021;152:135-142.
PubMed Abstract available

LIANG P, Qi L, Guo T, You X, et al
A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
Lung Cancer. 2021;152:193-195.
PubMed

MA H, Zhang Q, Duan Q, Zhang Q, et al
Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
Lung Cancer. 2021;152:196-198.
PubMed

BLAKE-CERDA M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, et al
Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Lung Cancer. 2021;152:119-126.
PubMed Abstract available

GENDARME S, Matton L, Antoine M, Kerrou K, et al
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
Lung Cancer. 2021;152:94-97.
PubMed Abstract available

BERGER I, Simpson S, Friedberg JS, Culligan MJ, et al
CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.
Lung Cancer. 2021;152:34-38.
PubMed Abstract available

CHAE M, Jeon JH, Chung JH, Lee SY, et al
Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection.
Lung Cancer. 2021;152:21-26.
PubMed Abstract available

KWOK WC, Cheong TF, Chiang KY, Ho JCM, et al
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid.
Lung Cancer. 2021;152:15-20.
PubMed Abstract available

GHIRARDELLI P, Franceschini D, D'Aveni A, Dominici L, et al
Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
Lung Cancer. 2021;152:1-6.
PubMed Abstract available

January 2021

HEUVELMANS MA, van Ooijen PMA, Ather S, Silva CF, et al
Lung cancer prediction by Deep Learning to identify benign lung nodules.
Lung Cancer. 2021;154:1-4.
PubMed Abstract available

ZOU Y, Wang Y, Jiang Z, Zhou Y, et al
Breath profile as composite biomarkers for lung cancer diagnosis.
Lung Cancer. 2021 Jan 30. pii: S0169-5002(21)00038.
PubMed Abstract available

GOMES F, Faivre-Finn C, Mistry H, Bezjak A, et al
Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
Lung Cancer. 2021;153:165-170.
PubMed Abstract available

FRIEDES C, Chakrabarti T, Olson S, Prichett L, et al
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
Lung Cancer. 2021;154:36-43.
PubMed Abstract available

EICHHORN F, Klotz LV, Kriegsmann M, Bischoff H, et al
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
Lung Cancer. 2021;153:150-157.
PubMed Abstract available

CHU X, Zhao J, Zhou J, Zhou F, et al
Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020
Lung Cancer. 2021 Jan 15. pii: S0169-5002(21)00015.
PubMed

HASHEMI S, Fransen MF, Niemeijer A, Ben Taleb N, et al
Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
Lung Cancer. 2021;153:81-89.
PubMed Abstract available

ZHOU J, Yu X, Hou L, Zhao J, et al
Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
Lung Cancer. 2021;153:143-149.
PubMed Abstract available

TAKAGI H, Zhao S, Muto S, Yokouchi H, et al
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using (125)I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
Lung Cancer. 2021;153:134-142.
PubMed Abstract available

CHEN D, Kang P, Tao S, Li Q, et al
Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer.
Lung Cancer. 2021;153:99-107.
PubMed Abstract available

OHTAKI Y, Shimizu K, Suzuki H, Suzuki K, et al
Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
Lung Cancer. 2021;153:108-116.
PubMed Abstract available

IKEDA T, Kadota K, Yoshida C, Ishikawa R, et al
The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a High risk of recurrence after resection of lung carcinoma.
Lung Cancer. 2021;153:49-55.
PubMed Abstract available

PROVENCIO M, Majem M, Guirado M, Massuti B, et al
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of su
Lung Cancer. 2021;153:25-34.
PubMed Abstract available

SANDFELD-PAULSEN B, Aggerholm-Pedersen N, Winther-Larsen A
Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study.
Lung Cancer. 2021;153:42-48.
PubMed Abstract available

LI Z, Lin Y, Chi X, Xu M, et al
Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.
Lung Cancer. 2021 Jan 8. pii: S0169-5002(21)00007.
PubMed

BRACKEN-CLARKE D, Kapoor D, Baird AM, Buchanan PJ, et al
Vaping and lung cancer - A review of current data and recommendations.
Lung Cancer. 2021;153:11-20.
PubMed Abstract available

YANG ZY, Liu ZY, Mu CY, Jiang JH, et al
Letter: Exploring the accuracy of biopsy in diagnosis of pulmonary sarcomatoid carcinoma.
Lung Cancer. 2021;151:97.
PubMed

LI X, Zhang D, Li B, Zou B, et al
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Lung Cancer. 2021;151:39-43.
PubMed Abstract available

FAIVRE-FINN C, Spigel DR, Senan S, Langer C, et al
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Lung Cancer. 2021;151:30-38.
PubMed Abstract available

LI M, Tang Q, Chen S, Wang Y, et al
A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
Lung Cancer. 2021;151:98-100.
PubMed

BUIKHUISEN WA, Steinbusch LC, Kodach LL, Tesselaar MET, et al
Risk of second primary malignancies among patients with carcinoid of the lung.
Lung Cancer. 2021;151:5-7.
PubMed Abstract available

XIONG L, Li X, Chen D, Li S, et al
GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
Lung Cancer. 2021;151:104-105.
PubMed

TAKAHASHI T, Umeguchi H, Tateishi A, Yoshida T, et al
Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
Lung Cancer. 2021;151:1-4.
PubMed Abstract available

BLONS H, Oudart JB, Merlio JP, Debieuvre D, et al
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
Lung Cancer. 2021;151:69-75.
PubMed Abstract available

WANG H, Shan Q, Guo J, Han X, et al
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Lung Cancer. 2021;151:76-83.
PubMed Abstract available

December 2020

DURHAM DD, Croswell JM, Marcus PM
Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
Lung Cancer. 2020;153:21-24.
PubMed Abstract available

ABBAR B, De Castelbajac V, Gougis P, Assoun S, et al
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
Lung Cancer. 2020;152:109-118.
PubMed Abstract available

LOBEFARO R, Viscardi G, Di Liello R, Massa G, et al
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lung Cancer. 2020;152:165-173.
PubMed Abstract available

RONDEN MI, Bahce I, Hashemi SMS, Dickhoff C, et al
Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
Lung Cancer. 2020;152:149-156.
PubMed Abstract available

BRAILLON A
Lung cancer outcomes: Are BMI and race clinically relevant?
Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30749.
PubMed

SHIBATA Y, Matsumoto S, Yoh K, Goto K, et al
Evaluation of variant frequency in SARS-CoV-2 infection-related genes utilizing lung cancer genomic database.
Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30733.
PubMed

CASIRAGHI M, Sedda G, Del Signore E, Piperno G, et al
Surgery for small cell lung cancer: When and how.
Lung Cancer. 2020;152:71-77.
PubMed Abstract available

MATSUURA Y, Ichinose J, Nakao M, Ninomiya H, et al
Outcomes of nodal upstaging comparing video-assisted thoracoscopic surgery versus open thoracotomy for lung cancer.
Lung Cancer. 2020;152:78-85.
PubMed Abstract available

DE MARINIS F, Laktionov KK, Poltoratskiy A, Egorova I, et al
Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Lung Cancer. 2020;152:127-134.
PubMed Abstract available

THOMAS PA, Couderc AL, Boulate D, Greillier L, et al
Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?
Lung Cancer. 2020;152:86-93.
PubMed Abstract available

PENG W, Pu X, Jiang M, Wang J, et al
Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Lung Cancer. 2020;152:66-70.
PubMed Abstract available

YANG X, Man J, Chen H, Zhang T, et al
Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis.
Lung Cancer. 2020;152:49-57.
PubMed Abstract available

TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Lung Cancer. 2020;152:27-33.
PubMed Abstract available

JIANG M, Fares AF, Shepshelovich D, Yang P, et al
The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.
Lung Cancer. 2020;152:58-65.
PubMed Abstract available

YANG GJ, Li J, Xu HY, Sun Y, et al
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
Lung Cancer. 2020;152:39-48.
PubMed Abstract available

VIGARIOS E, Rabeau A, Mazieres J, Sibaud V, et al
Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management.
Lung Cancer. 2020 Dec 4. pii: S0169-5002(20)30714.
PubMed

MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
Lung Cancer. 2020 Dec 2. pii: S0169-5002(20)30691.
PubMed

MI J, Xu Q, Lizaso A, Zhang Y, et al
A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".
Lung Cancer. 2020;150:259-260.
PubMed

LIU L, Xu Q, Lizaso A, Zhang Y, et al
A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
Lung Cancer. 2020;150:254-255.
PubMed

LI X, Wang R, Wang L
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Lung Cancer. 2020;150:256-258.
PubMed

LI X, Wang L, Yu J
ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Lung Cancer. 2020;150:252-253.
PubMed

November 2020

ELFVING H, Brostrom E, Moens LNJ, Almlof J, et al
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
Lung Cancer. 2020;151:53-59.
PubMed Abstract available

MCCANN B, Muhr R, O'Rourke N, Milroy R, et al
ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care.
Lung Cancer. 2020;151:44-52.
PubMed Abstract available

LU S, Wang J, Cheng Y, Mok T, et al
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lung Cancer. 2020;152:7-14.
PubMed Abstract available

GARON EB, Kim JS, Govindan R
Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
Lung Cancer. 2020;151:25-29.
PubMed Abstract available

YAMAMOTO N, Seto T, Nishio M, Goto K, et al
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Lung Cancer. 2020;151:20-24.
PubMed Abstract available

ARAKAWA S, Yoshida T, Shirasawa M, Takayanagi D, et al
RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.
Lung Cancer. 2020 Nov 20. pii: S0169-5002(20)30690.
PubMed

LEE Y, Joo J, Lee YJ, Lee EK, et al
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
Lung Cancer. 2020;151:8-15.
PubMed Abstract available

SONI S, Rastogi A, Prasad KT, Behera D, et al
Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
Lung Cancer. 2020;151:16-19.
PubMed Abstract available

TSITSIAS T, Okiror L, Veres L, King J, et al
New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery.
Lung Cancer. 2020 Nov 16. pii: S0169-5002(20)30680.
PubMed Abstract available

WAKUDA K, Yabe M, Kodama H, Nishioka N, et al
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Lung Cancer. 2020 Nov 15. pii: S0169-5002(20)30684.
PubMed Abstract available

WANG M, Zhang D, Wang G, Xia J, et al
HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
Lung Cancer. 2020 Nov 13. pii: S0169-5002(20)30679.
PubMed

JOOSTEN PJM, Dickhoff C, van der Noort V, Klomp HM, et al
Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
Lung Cancer. 2020;150:209-215.
PubMed Abstract available

ZHOU Y, Wang B, Qu J, Yu F, et al
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
Lung Cancer. 2020;150:178-185.
PubMed Abstract available

VICKERS AJ, Frese K, Galvin M, Carter M, et al
Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
Lung Cancer. 2020;150:216-220.
PubMed Abstract available

GASSA A, Fassunke J, Schueten S, Kuhlmann L, et al
Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Lung Cancer. 2020 Nov 5. pii: S0169-5002(20)30670.
PubMed Abstract available

WU YL, Shi Y, Tan DSW, Xiaoqing L, et al
Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
Lung Cancer. 2020;150:240-246.
PubMed Abstract available

LI JJN, Karim K, Sung M, Le LW, et al
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
Lung Cancer. 2020;150:159-163.
PubMed Abstract available

BISHNOI R, Shah C, Blaes A, Bian J, et al
Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
Lung Cancer. 2020;150:172-177.
PubMed Abstract available

GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Lung Cancer. 2020 Nov 2. pii: S0169-5002(20)30663.
PubMed Abstract available

October 2020

YUN JK, Park I, Kim HR, Choi YS, et al
Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.
Lung Cancer. 2020;150:201-208.
PubMed Abstract available

BERSANELLI M, Buti S, Giannarelli D, Leonetti A, et al
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Lung Cancer. 2020;150:123-131.
PubMed Abstract available

FAEHLING M, Schumann C, Christopoulos P, Hoffknecht P, et al
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Lung Cancer. 2020;150:114-122.
PubMed Abstract available

ZENG C, Gao Y, Xiong J, Lu J, et al
Tumor-infiltrating CD8(+) T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
Lung Cancer. 2020;150:139-144.
PubMed Abstract available

YOTSUKURA M, Asamura H, Suzuki S, Asakura K, et al
Corrigendum to "Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma" [Lung Cancer 145 (2020) 158-166].
Lung Cancer. 2020 Oct 13. pii: S0169-5002(20)30639.
PubMed

SUBBIAH V, Paz-Ares L, Besse B, Moreno V, et al
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Lung Cancer. 2020;150:90-96.
PubMed Abstract available

WANG L, Ruan M, Lei B, Yan H, et al
The potential of (18)F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.
Lung Cancer. 2020;150:44-52.
PubMed Abstract available

ZENG J, Mao WM, Chen QX, Luo TB, et al
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Lung Cancer. 2020;150:164-171.
PubMed Abstract available

GARCIA-CAMPELO R, Arrieta O, Massuti B, Rodriguez-Abreu D, et al
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Lung Cancer. 2020;150:62-69.
PubMed Abstract available

INAGAKI Y, Tamiya A
Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'.
Lung Cancer. 2020;148:179-180.
PubMed

September 2020

SHAO D, Cheng Y, Yuan ZS, Jiang BY, et al
Value of interim (18)F-FDG PET/CT for predicting progression-free survival in stage B/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
Lung Cancer. 2020;149:137-143.
PubMed Abstract available

TAO H, Shi L, Zhou A, Li H, et al
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Lung Cancer. 2020;149:154-161.
PubMed Abstract available

ZHANG L, Yip R, Jirapatnakul A, Li M, et al
Lung cancer screening intervals based on cancer risk.
Lung Cancer. 2020;149:113-119.
PubMed Abstract available

TAKEDA-MIYATA N, Konishi E, Tanaka T, Shimomura M, et al
Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer.
Lung Cancer. 2020;149:61-67.
PubMed Abstract available

FUKUMOTO K, Mori S, Shintani Y, Okami J, et al
Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study.
Lung Cancer. 2020;149:120-129.
PubMed Abstract available

GOLDMAN JW, Garassino MC, Chen Y, Ozguroglu M, et al
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Lung Cancer. 2020;149:46-52.
PubMed Abstract available

REISSIG TM, Sara L, Ting S, Reis H, et al
ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Lung Cancer. 2020;149:10-16.
PubMed Abstract available

LIU X, Hong L, Nilsson M, Hubert SM, et al
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
Lung Cancer. 2020;149:33-40.
PubMed Abstract available

LI J, Wang Y, Zhang B, Xu J, et al
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
Lung Cancer. 2020;149:17-22.
PubMed Abstract available

ALBORELLI I, Bratic Hench I, Chijioke O, Prince SS, et al
Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
Lung Cancer. 2020;149:84-89.
PubMed Abstract available

VOONG KR, Naidoo J
Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.
Lung Cancer. 2020 Sep 5. pii: S0169-5002(20)30596.
PubMed

BERGHMANS T, Lievens Y, Aapro M, Baird AM, et al
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.
Lung Cancer. 2020;150:221-239.
PubMed Abstract available

August 2020

BAUM P, Diers J, Haag J, Klotz L, et al
Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany.
Lung Cancer. 2020;149:78-83.
PubMed Abstract available

CHU X, Zhao J, Zhou J, Zhou F, et al
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Lung Cancer. 2020;150:76-82.
PubMed Abstract available

CHRISTOPOULOS P, Kirchner M, Roeper J, Saalfeld F, et al
Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing.
Lung Cancer. 2020;148:105-112.
PubMed Abstract available

SUDA K, Murakami I, Obata K, Sakai K, et al
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
Lung Cancer. 2020;148:100-104.
PubMed Abstract available

ISMAIL RK, Schramel FMNH, van Dartel M, Hilarius DL, et al
The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients.
Lung Cancer. 2020;149:68-77.
PubMed Abstract available

ANG L, Chan CPY, Yau WP, Seow WJ, et al
Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis.
Lung Cancer. 2020;148:129-137.
PubMed Abstract available

YAMAMOTO M, Serizawa T, Sato Y, Higuchi Y, et al
Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65-74 years.
Lung Cancer. 2020;149:103-112.
PubMed Abstract available

VAN VEGGEL B, de Langen AJ
A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".
Lung Cancer. 2020 Aug 8. pii: S0169-5002(20)30555.
PubMed

RECK M, Syrigos K, Miliauskas S, Zochbauer-Muller S, et al
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Lung Cancer. 2020;148:159-165.
PubMed Abstract available

WADDLE MR, Ko SJ, May J, Kaleem T, et al
Improving identification of candidates for lung cancer screening in a high risk population.
Lung Cancer. 2020;148:79-85.
PubMed Abstract available

MADISON R, Schrock AB, Castellanos E, Gregg JP, et al
Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Lung Cancer. 2020;148:69-78.
PubMed Abstract available

SURYAVANSHI M, Jaipuria J, Panigrahi MK, Goyal N, et al
CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.
Lung Cancer. 2020;148:33-39.
PubMed Abstract available

MARCHIONI A, Andrisani D, Tonelli R, Piro R, et al
Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE).
Lung Cancer. 2020;148:40-47.
PubMed Abstract available

CHANG HL, Wei PJ, Wu KL, Huang HL, et al
Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
Lung Cancer. 2020;146:376-377.
PubMed

WANG K, Liu Y, Hu T, Liu Y, et al
The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
Lung Cancer. 2020;146:373-375.
PubMed

July 2020

BARTLETT EC, Kemp SV, Ridge CA, Desai SR, et al
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
Lung Cancer. 2020;148:12-19.
PubMed Abstract available

ROJO F, Corassa M, Mavroudis D, Oz AB, et al
International real-world study of DLL3 expression in patients with small cell lung cancer.
Lung Cancer. 2020;147:237-243.
PubMed Abstract available

YOUNG K, Jiang H, Marquez M, Yeung J, et al
Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.
Lung Cancer. 2020;147:214-220.
PubMed Abstract available

VAD-NIELSEN J, Meldgaard P, Sorensen BS, Nielsen AL, et al
Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.
Lung Cancer. 2020;147:244-251.
PubMed Abstract available

YANG G, Xu H, Yang L, Xu F, et al
Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
Lung Cancer. 2020;147:229-236.
PubMed Abstract available

ZHENG J, Cao H, Li Y, Rao C, et al
Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
Lung Cancer. 2020;147:130-136.
PubMed Abstract available

FAN Y, Chen J, Zhou C, Wang H, et al
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Lung Cancer. 2020;147:209-213.
PubMed Abstract available

VARLOTTO JM, Voland R, DeCamp MM, Rava P, et al
The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer.
Lung Cancer. 2020;147:115-122.
PubMed Abstract available

BEN DORI S, Aizic A, Sabo E, Hershkovitz D, et al
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
Lung Cancer. 2020;147:91-98.
PubMed Abstract available

SVEDBERG A, Bjorn N, Sigurgeirsson B, Pradhananga S, et al
Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Lung Cancer. 2020;147:106-114.
PubMed Abstract available

TOUMAZIS I, Bastani M, Han SS, Plevritis SK, et al
Risk-Based lung cancer screening: A systematic review.
Lung Cancer. 2020;147:154-186.
PubMed Abstract available

JIA XH, Xu H, Geng LY, Jiao M, et al
Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
Lung Cancer. 2020;147:143-153.
PubMed Abstract available

SUH JW, Jeong YH, Cho A, Kim DJ, et al
Corrigendum to "Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer" [Lung Cancer 142 (2020) 28-33].
Lung Cancer. 2020 Jul 8. pii: S0169-5002(20)30485.
PubMed

SUN C, Anraku M, Kawahara T, Karasaki T, et al
Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery.
Lung Cancer. 2020;147:71-76.
PubMed Abstract available

HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
A reply to "A modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing".
Lung Cancer. 2020 Jul 3. pii: S0169-5002(20)30515.
PubMed

REMON J, Nadal E, Domine M, Ruffinelli J, et al
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
Lung Cancer. 2020;147:83-90.
PubMed Abstract available

WANG Q, Li X, Ren S, Su C, et al
HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
Lung Cancer. 2020;147:99-105.
PubMed Abstract available

DI NOIA V, D'Aveni A, Squadroni M, Beretta GD, et al
Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
Lung Cancer. 2020;145:208-210.
PubMed

CHEN H, Louie AV
High risk, same reward?
Lung Cancer. 2020;145:221.
PubMed

BALDINI E, Tibaldi C
A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
Lung Cancer. 2020;145:226.
PubMed

INDINI A, Rijavec E, Grossi F
Immune related adverse events and response to immunotherapy: Focus on corticosteroids.
Lung Cancer. 2020;145:225.
PubMed

June 2020

CORSINI EM, Wang Q, Tran HT, Mitchell KG, et al
Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.
Lung Cancer. 2020;146:303-309.
PubMed Abstract available

CUI W, Franchini F, Alexander M, Officer A, et al
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
Lung Cancer. 2020;146:310-317.
PubMed Abstract available

SUNG JH, Brown MC, Perez-Cosio A, Pratt L, et al
Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study.
Lung Cancer. 2020;147:1-11.
PubMed Abstract available

GACHECHILADZE M, Skarda J, Skanderova D, Uberall I, et al
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
Lung Cancer. 2020;147:30-38.
PubMed Abstract available

CHEN C, Wang W, Yu Z, Tian S, et al
Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.
Lung Cancer. 2020;146:290-296.
PubMed Abstract available

SOMMER MS, Vibe-Petersen J, Staerkind MB, Langer SW, et al
Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial.
Lung Cancer. 2020;146:285-289.
PubMed Abstract available

LU S, Chen G, Sun Y, Sun S, et al
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Lung Cancer. 2020;146:252-262.
PubMed Abstract available

HURKMANS DP, Tamminga M, van Es B, Peters T, et al
Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.
Lung Cancer. 2020;146:341-349.
PubMed Abstract available

CHEN LN, Spivack J, Cao T, Saqi A, et al
Characteristics and outcomes of lung cancer in solid organ transplant recipients.
Lung Cancer. 2020;146:297-302.
PubMed Abstract available

WANG Z, Zhao J, Ma Z, Cui J, et al
A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
Lung Cancer. 2020;147:259-268.
PubMed Abstract available

KOBAYASHI K, Soejima K, Fukunaga K, Shintani Y, et al
Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
Lung Cancer. 2020;146:236-243.
PubMed Abstract available

WANG W, Cheng G, Zhang G, Song Z, et al
Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
Lung Cancer. 2020;146:224-229.
PubMed Abstract available

GAGNE A, Orain M, Ionescu D, Tsao MS, et al
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
Lung Cancer. 2020;146:276-284.
PubMed Abstract available

NICOSIA L, Di Muzio J, Agolli L, Alongi F, et al
What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?
Lung Cancer. 2020;146:263-275.
PubMed Abstract available

HUANG M, Insinga RP, Burke T, Zhang Y, et al
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
Lung Cancer. 2020 Jun 17. pii: S0169-5002(20)30489.
PubMed

LEI Y, Feng H, Qiang H, Shang Z, et al
Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.
Lung Cancer. 2020;146:244-251.
PubMed Abstract available

LU M, Hu C, Wu F, Shu L, et al
MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
Lung Cancer. 2020;147:193-197.
PubMed Abstract available

STAHEL RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, et al
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug.
Lung Cancer. 2020;146:217-223.
PubMed Abstract available

IGAWA S, Naoki K, Shintani Y, Sekine I, et al
Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
Lung Cancer. 2020;146:160-164.
PubMed Abstract available

MENG P, Koopman B, Kok K, Ter Elst A, et al
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Lung Cancer. 2020 Jun 4. pii: S0169-5002(20)30472.
PubMed Abstract available

FORNACON-WOOD I, Faivre-Finn C, O'Connor JPB, Price GJ, et al
Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.
Lung Cancer. 2020;146:197-208.
PubMed Abstract available

CHEN D, Chen C, Chen Y
Letter to the editor concerning 'Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer'.
Lung Cancer. 2020;144:92.
PubMed

May 2020

JUNG HA, Sun JM, Lee SH, Ahn JS, et al
Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Lung Cancer. 2020;146:112-119.
PubMed Abstract available

JUNG HA, Noh JM, Sun JM, Lee SH, et al
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Lung Cancer. 2020;146:23-29.
PubMed Abstract available

ITO M, Kanda S, Yoshida T, Okuma Y, et al
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
PubMed Abstract available

ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
Covid-19 and lung cancer: A greater fatality rate?
Lung Cancer. 2020;146:19-22.
PubMed Abstract available

YANG YM, Jang Y, Lee SH, Kang B, et al
AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
Lung Cancer. 2020;146:70-77.
PubMed Abstract available

ZHENG J, Zhu Y, Sun K, Shen Q, et al
Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
Lung Cancer. 2020;146:209-216.
PubMed Abstract available

HAN J, Tian K, Yang J, Gong Y, et al
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
Lung Cancer. 2020;146:42-49.
PubMed Abstract available

RECK M, Luft A, Bondarenko I, Shevnia S, et al
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
Lung Cancer. 2020;146:12-18.
PubMed Abstract available

LIAO Z, Rivin Del Campo E, Salem A, Pang Q, et al
Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.
Lung Cancer. 2020;146:230-235.
PubMed Abstract available

TESSEMA M, Tassew DD, Yingling CM, Do K, et al
Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients.
Lung Cancer. 2020;146:189-196.
PubMed Abstract available

IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
Lung Cancer. 2020;146:97-104.
PubMed Abstract available

LEAL JL, Peters G, Szaumkessel M, Leong T, et al
NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
Lung Cancer. 2020;146:154-159.
PubMed Abstract available

ZHAO D, Mambetsariev I, Li H, Chen C, et al
Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
Lung Cancer. 2020;146:174-181.
PubMed Abstract available

LAM ACL, Aggarwal R, Cheung S, Stewart EL, et al
Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis.
Lung Cancer. 2020;146:134-144.
PubMed Abstract available

SHI R, Filho SNM, Li M, Fares A, et al
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
Lung Cancer. 2020;146:78-85.
PubMed Abstract available

SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
Lung Cancer. 2020;146:36-41.
PubMed Abstract available

CHAN GH, Gwee YX, Low JL, Huang Y, et al
Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
Lung Cancer. 2020;146:145-153.
PubMed Abstract available

MCFARLAND DC
A comment on "Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms".
Lung Cancer. 2020 May 20. pii: S0169-5002(20)30429.
PubMed

ZENKE Y, Niho S, Umemura S, Ishihara M, et al
Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged >/=75 years with squamous-cell lung cancer: TORG1322.
Lung Cancer. 2020;146:182-188.
PubMed Abstract available

CRENGLE S
Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233-240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004.
Lung Cancer. 2020 May 16. pii: S0169-5002(20)30377.
PubMed

YUN JK, Lee GD, Choi S, Kim HR, et al
Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
Lung Cancer. 2020;146:105-111.
PubMed Abstract available

ROSSI G, Caruso D, Nosseir S, Banchelli I, et al
A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing.
Lung Cancer. 2020 May 14. pii: S0169-5002(20)30430.
PubMed

SUN F, Franks K, Murray L, Lilley J, et al
Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?
Lung Cancer. 2020;146:1-5.
PubMed Abstract available

MORGENSZTERN D, Johnson M, Rudin CM, Rossi M, et al
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
Lung Cancer. 2020;145:126-131.
PubMed Abstract available

ISAKA T, Ito H, Nakayama H, Yokose T, et al
Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Lung Cancer. 2020;145:111-118.
PubMed Abstract available

BEAGAN JJ, Bach S, van Boerdonk RA, van Dijk E, et al
Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
Lung Cancer. 2020;145:173-180.
PubMed Abstract available

QUIST M, Langer SW, Lillelund C, Winther L, et al
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial.
Lung Cancer. 2020;145:76-82.
PubMed Abstract available

DALL'OLIO FG, Maggio I, Massucci M, Mollica V, et al
ECOG performance status >/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Lung Cancer. 2020;145:95-104.
PubMed Abstract available

ROSSI D
Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.
Lung Cancer. 2020;145:83-84.
PubMed Abstract available

DREVET G, Duruisseaux M, Lafitte C, Derberne M, et al
A reply to "A comment on "Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience".
Lung Cancer. 2020 May 6. pii: S0169-5002(20)30406.
PubMed

HOFMAN V, Benzaquen J, Heeke S, Lassalle S, et al
Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
Lung Cancer. 2020;145:58-62.
PubMed Abstract available

CHEN V, Iwama E, Kim IK, Giaccone G, et al
Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
Lung Cancer. 2020;145:48-57.
PubMed Abstract available

TAKADA K, Takamori S, Yoneshima Y, Tanaka K, et al
Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
Lung Cancer. 2020;145:18-26.
PubMed Abstract available

SERENO M, Gutierrez-Gutierrez G, Sandoval C, Falagan S, et al
A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
Lung Cancer. 2020 May 4. pii: S0169-5002(20)30399.
PubMed

HANDRA-LUCA A
C-Myc in mucinous colloid carcinoma of the lung.
Lung Cancer. 2020;143:93-94.
PubMed

SMUK G, Pajor G, Szuhai K, Morreau H, et al
Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Lung Cancer. 2020;143:80-85.
PubMed Abstract available

OKUNO T, Arakawa S, Yoshida T, Ohe Y, et al
Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
Lung Cancer. 2020;143:95-96.
PubMed

KNEUERTZ PJ, Carbone DP, D'Souza DM, Shilo K, et al
Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Lung Cancer. 2020;143:60-66.
PubMed Abstract available

ZHOU Y, Jiang W, Zeng L, Mi J, et al
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Lung Cancer. 2020;143:55-59.
PubMed Abstract available

SHERMAN S, Rotem O, Shochat T, Zer A, et al
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
Lung Cancer. 2020;143:40-46.
PubMed Abstract available

TREJO BITTAR HE, Jerome JA, Hartman D, Pantanowitz L, et al
Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
Lung Cancer. 2020;143:12-18.
PubMed Abstract available

April 2020

LIN YT, Tsai TH, Wu SG, Liu YN, et al
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
Lung Cancer. 2020;145:1-9.
PubMed Abstract available

THOMAS R, Chen YH, Hatabu H, Mak RH, et al
Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.
Lung Cancer. 2020;145:132-139.
PubMed Abstract available

DENG J, Zhao M, Wang T, She Y, et al
A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
Lung Cancer. 2020;145:33-39.
PubMed Abstract available

SOLOMON BJ, Kim EE, Winter M, Monti K, et al
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
Lung Cancer. 2020;145:167-172.
PubMed Abstract available

SCHEFFLER M, Holzem A, Kron A, Nogova L, et al
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Lung Cancer. 2020;144:40-48.
PubMed Abstract available

LIU B, Henschke CI, Flores RM, Taioli E, et al
Serum cotinine verification of self-reported smoking status among adults eligible for lung cancer screening in the 1999-2018 National Health and Nutrition Examination Survey.
Lung Cancer. 2020;144:49-56.
PubMed Abstract available

POPAT S, Grohe C, Corral J, Reck M, et al
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Lung Cancer. 2020;144:76-84.
PubMed Abstract available

DE RUITER JC, Heineman DJ, Daniels JM, van Diessen JN, et al
The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
Lung Cancer. 2020;144:64-70.
PubMed Abstract available

BREADNER D, Blanchette P, Shanmuganathan S, Boldt RG, et al
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
Lung Cancer. 2020;144:57-63.
PubMed Abstract available

JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Lung Cancer. 2020 Apr 18. pii: S0169-5002(20)30337.
PubMed Abstract available

GOFFIN JR
Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
Lung Cancer. 2020 Apr 4. pii: S0169-5002(20)30351.
PubMed

ESCOIN-PEREZ C, Blasco S, Juan-Vidal O
Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
Lung Cancer. 2020;144:1-9.
PubMed Abstract available

THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
Reply to the letter-to-the editor "Hospital volume and the case for centralisation of surgical services".
Lung Cancer. 2020;142:140-141.
PubMed

STIRLING R, Stenger M, Zalcberg J
Comment on: 'Hospital lung surgery volume and patient outcomes'.
Lung Cancer. 2020;142:138-139.
PubMed

MOODLEY S, Lian EY, Crupi MJF, Hyndman BD, et al
RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.
Lung Cancer. 2020;142:123-131.
PubMed Abstract available

SALA L, Mancin M, Pastore A, Seminati D, et al
Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
Lung Cancer. 2020;142:120-122.
PubMed Abstract available

CHEN HF, Wang WX, Xu CW, Huang LC, et al
A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Lung Cancer. 2020;142:59-62.
PubMed Abstract available

ZUCALI PA, Perrino M, De Vincenzo F, Giordano L, et al
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Lung Cancer. 2020;142:132-137.
PubMed Abstract available

CHAN OSH, Lam KC, Li JYC, Choi FPT, et al
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
Lung Cancer. 2020;142:41-46.
PubMed Abstract available

SUH JW, Jeong YH, Cho A, Kim DJ, et al
Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer(1).
Lung Cancer. 2020;142:28-33.
PubMed Abstract available

AN N, Leng X, Wang X, Sun Y, et al
Survival comparison of Three histological subtypes of lung squamous cell carcinoma: A population-based propensity score matching analysis.
Lung Cancer. 2020;142:13-19.
PubMed Abstract available

March 2020

FRUH M, Panje CM, Reck M, Blackhall F, et al
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
Lung Cancer. 2020;146:6-11.
PubMed Abstract available

VERONESI G, Navone N, Novellis P, Dieci E, et al
Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
Lung Cancer. 2020;143:73-79.
PubMed Abstract available

BOYSEN FYNBOE EBERT E, McCulloch T, Holmskov Hansen K, Linnet H, et al
Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Lung Cancer. 2020;143:67-72.
PubMed Abstract available

KARAYAMA M, Yoshizawa N, Sugiyama M, Mori K, et al
Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
Lung Cancer. 2020;143:47-54.
PubMed Abstract available

MA L, Zhang Q, Dong Y, Li H, et al
SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30347.
PubMed

YANG G, Li J, Xu H, Yang Y, et al
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30344.
PubMed Abstract available

SANCHIS-BORJA M, Ricordel C, Chiappa AM, Hureaux J, et al
Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
Lung Cancer. 2020;143:36-39.
PubMed Abstract available

EIDE IJZ, Helland A, Ekman S, Mellemgaard A, et al
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Lung Cancer. 2020;143:27-35.
PubMed Abstract available

PETERS S, Shaw AT, Besse B, Felip E, et al
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Lung Cancer. 2020;144:10-19.
PubMed Abstract available

SHEINSON D, Wong WB, Wu N, Mansfield AS, et al
Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
Lung Cancer. 2020;143:86-92.
PubMed Abstract available

ROCH B, Coffy A, Jean-Baptiste S, Palaysi E, et al
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
Lung Cancer. 2020;143:19-26.
PubMed Abstract available

ITO M, Miyata Y, Tsutani Y, Ito H, et al
Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Lung Cancer. 2020;141:107-113.
PubMed Abstract available

GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
Cytology for PD-L1 testing: A systematic review.
Lung Cancer. 2020;141:101-106.
PubMed Abstract available

LI C, Shen Y, Hu F, Chu T, et al
Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
Lung Cancer. 2020;141:72-77.
PubMed Abstract available

ZHAO J, Lin G, Zhuo M, Fan Z, et al
Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
Lung Cancer. 2020;141:114-118.
PubMed Abstract available

February 2020

TANG Y, Xia B, Xie R, Xu X, et al
Erratum to "Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI" [Lung Cancer, 140 (February) (2020) 65-70].
Lung Cancer. 2020 Feb 27. pii: S0169-5002(20)30278.
PubMed

KHORRAMI M, Bera K, Leo P, Vaidya P, et al
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study.
Lung Cancer. 2020;142:90-97.
PubMed Abstract available

HIRPARA DH, Gupta V, Davis LE, Zhao H, et al
Severe symptoms persist for Up to one year after diagnosis of stage I-III lung cancer: An analysis of province-wide patient reported outcomes.
Lung Cancer. 2020;142:80-89.
PubMed Abstract available

CORRAO G, Marvaso G, Ferrara R, Lo Russo G, et al
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases.
Lung Cancer. 2020;142:70-79.
PubMed Abstract available

THEELEN WS, de Jong MC, Baas P
Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
Lung Cancer. 2020;142:106-113.
PubMed Abstract available

PERTEJO-FERNANDEZ A, Ricciuti B, Hammond SP, Marty FM, et al
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
Lung Cancer. 2020 Feb 24. pii: S0169-5002(20)30310.
PubMed Abstract available

CHEN K, Cheng G, Zhang F, Zhu G, et al
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Lung Cancer. 2020;142:98-105.
PubMed Abstract available

BESSE B, Garrido P, Cortot AB, Johnson M, et al
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Lung Cancer. 2020;142:63-69.
PubMed Abstract available

BOUSEMA JE, Heineman DJ, Dijkgraaf MGW, Annema JT, et al
Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit - Surgery.
Lung Cancer. 2020;142:51-58.
PubMed Abstract available

FINKE I, Behrens G, Schwettmann L, Gerken M, et al
Socioeconomic differences and lung cancer survival in Germany: Investigation based on population-based clinical cancer registration.
Lung Cancer. 2020;142:1-8.
PubMed Abstract available

WANG F, Qin J, Xie F, Wu Q, et al
Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
Lung Cancer. 2020;140:118-120.
PubMed

LAM WS, Creaney J, Chen FK, Chin WL, et al
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Lung Cancer. 2020;140:87-92.
PubMed Abstract available

WU H, Dong S, Li X, Shi L, et al
Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
Lung Cancer. 2020;140:80-86.
PubMed Abstract available

REALE ML, Chiari R, Tiseo M, Vitiello F, et al
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Lung Cancer. 2020;140:71-79.
PubMed Abstract available

BALDINI E, Lunghi A, Cortesi E, Turci D, et al
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Lung Cancer. 2020;140:59-64.
PubMed Abstract available

GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Lung Cancer. 2020;140:42-45.
PubMed Abstract available

SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
Lung Cancer. 2020;140:35-41.
PubMed Abstract available

EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
Lung Cancer. 2020;140:116-117.
PubMed

SHOJI S, Watanabe S, Takamura K, Umezu H, et al
First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
Lung Cancer. 2020;140:113-115.
PubMed

January 2020

ALEXANDER M, Pavlakis N, John T, O'Connell R, et al
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
Lung Cancer. 2020;142:34-40.
PubMed Abstract available

ZHUANG H, Jiang W, Cheng W, Qian K, et al
Corrigendum to "Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis" [Lung Cancer 68 (1) (2010) 27-38].
Lung Cancer. 2020 Jan 16. pii: S0169-5002(20)30003.
PubMed

WOLFF HB, Alberts L, van der Linden N, Bongers ML, et al
Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.
Lung Cancer. 2020;141:89-96.
PubMed Abstract available

JOHNSON AM, Johnson A, Hines RB, Mohammadi R, et al
Neighborhood context and non-small cell lung cancer outcomes in Florida non-elderly patients by race/ethnicity.
Lung Cancer. 2020;142:20-27.
PubMed Abstract available

RICE SJ, Liu X, Hyland V, Liu Z, et al
Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
Lung Cancer. 2020;141:97-100.
PubMed Abstract available

ZENG L, Xiao L, Jiang W, Yang H, et al
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Lung Cancer. 2020;141:82-88.
PubMed Abstract available

SERRA P, Centeno C, Sanz-Santos J, Torky M, et al
Is it necessary to sample the contralateral nodal stations by EBUS-TBNA in patients with lung cancer and clinical N0 / N1 on PET-CT?
Lung Cancer. 2020;142:9-12.
PubMed Abstract available

JONES GS, Elimian K, Baldwin DR, Hubbard RB, et al
A systematic review of survival following anti-cancer treatment for small cell lung cancer.
Lung Cancer. 2020;141:44-55.
PubMed Abstract available

NIHO S, Yoshida T, Akimoto T, Sakamaki K, et al
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Lung Cancer. 2020;141:64-71.
PubMed Abstract available

YOSHIMURA K, Inoue Y, Tsuchiya K, Karayama M, et al
Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Lung Cancer. 2020;141:21-31.
PubMed Abstract available

NAGASAKA M, Lehman A, Chlebowski R, Haynes BM, et al
COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report.
Lung Cancer. 2020;141:78-81.
PubMed Abstract available

HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer.
Lung Cancer. 2020;141:56-63.
PubMed Abstract available

CAO X, Ganti AK, Stinchcombe T, Wong ML, et al
Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
Lung Cancer. 2020;141:14-20.
PubMed Abstract available

BUGLIONE M, Jereczek-Fossa BA, Bonu ML, Franceschini D, et al
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Lung Cancer. 2020;141:1-8.
PubMed Abstract available

ZHOU F, Zhao W, Chen X, Zhang J, et al
Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF(V600E) mutation.
Lung Cancer. 2020;139:219-220.
PubMed

ZELTSMAN M, Dozier J, Vaghjiani RG, Poch A, et al
Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity.
Lung Cancer. 2020;139:68-72.
PubMed Abstract available

PINSKY P, Gierada DS
Long-term cancer risk associated with lung nodules observed on low-dose screening CT scans.
Lung Cancer. 2020;139:179-184.
PubMed Abstract available

MIYAKE N, Ochi N, Yamane H, Fukazawa T, et al
Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
Lung Cancer. 2020;139:170-178.
PubMed Abstract available

WIESWEG M, Herold T, Metzenmacher M, Eberhardt WE, et al
Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Lung Cancer. 2020;139:165-168.
PubMed Abstract available

YANG S, Mao S, Li X, Zhao C, et al
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Lung Cancer. 2020;139:133-139.
PubMed Abstract available

STOCKHAMMER P, Ploenes T, Theegarten D, Schuler M, et al
Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Lung Cancer. 2020;139:124-132.
PubMed Abstract available

ZHANG JT, Li Y, Yan LX, Zhu ZF, et al
Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Lung Cancer. 2020;139:118-123.
PubMed Abstract available

WANG B, Tang Y, Chen Y, Hamal P, et al
Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules.
Lung Cancer. 2020;139:103-110.
PubMed Abstract available

CHEN X, Pang Z, Wang Y, Bie F, et al
The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database.
Lung Cancer. 2020;139:94-102.
PubMed Abstract available

SOUSA AC, Silveira C, Janeiro A, Malveiro S, et al
Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
Lung Cancer. 2020;139:35-40.
PubMed Abstract available

CARACENI A, Lo Dico S, Zecca E, Brunelli C, et al
Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
Lung Cancer. 2020;139:13-17.
PubMed Abstract available

RIBEIRO MFSA, Alessi JVM, Oliveira LJC, Gongora ABL, et al
Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Lung Cancer. 2020;139:9-12.
PubMed Abstract available

December 2019

GIAJ LEVRA M, Cotte FE, Corre R, Calvet C, et al
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
Lung Cancer. 2019;140:99-106.
PubMed Abstract available

EBERT EBF, McCulloch T, Hansen KH, Linnet H, et al
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Lung Cancer. 2019;141:37-43.
PubMed Abstract available

SMIT HJM, Aerts J, van den Heuvel M, Hiltermann TJN, et al
Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Lung Cancer. 2019;140:107-112.
PubMed Abstract available

VAN VEGGEL B, Madeira R Santos JFV, Hashemi SMS, Paats MS, et al
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
Lung Cancer. 2019;141:9-13.
PubMed Abstract available

TOFFART AC, Asfari S, Mc Leer A, Reymond E, et al
Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing.
Lung Cancer. 2019;140:93-98.
PubMed Abstract available

TANG Y, Xia B, Xu X, Zhang M, et al
Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.
Lung Cancer. 2019;140:65-70.
PubMed Abstract available

NACHIRA D, Meacci E, Congedo MT, Chiappetta M, et al
Upstaging, centrality and survival in early stage non-small cell lung cancer video-assisted surgery: Lymph nodal upstaging in lung cancer surgery: is it really a surgical technique problem?
Lung Cancer. 2019 Dec 18. pii: S0169-5002(19)30774.
PubMed

GROSU HB, Manzanera A, Shivakumar S, Sun S, et al
Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.
Lung Cancer. 2019;140:55-58.
PubMed Abstract available

HELMINEN O, Valo J, Andersen H, Lautamaki A, et al
Real-world guideline-based treatment of lung cancer improves short- and long-term outcomes and resection rate: A population-based study.
Lung Cancer. 2019;140:1-7.
PubMed Abstract available

November 2019

KUBOTA K, Kunitoh H, Seto T, Shimada N, et al
Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Lung Cancer. 2019;141:32-36.
PubMed Abstract available

BLOM EF, Ten Haaf K, de Koning HJ
Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates.
Lung Cancer. 2019;139:200-206.
PubMed Abstract available

NAKAGAWA K, Hida T, Nokihara H, Morise M, et al
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Lung Cancer. 2019;139:195-199.
PubMed Abstract available

NARTEY Y, Stewart I, Khakwani A, Beattie V, et al
Is the English Cancer Patient Experience Survey representative? A comparative analysis with the National Lung Cancer Audit.
Lung Cancer. 2019;140:27-34.
PubMed Abstract available

SHIN SH, Jeong BH, Jhun BW, Yoo H, et al
The utility of endosonography for mediastinal staging of non-small cell lung cancer in patients with radiological N0 disease.
Lung Cancer. 2019;139:151-156.
PubMed Abstract available

TAN AC, Lai GGY, Tan GS, Poon SY, et al
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Lung Cancer. 2019;139:207-215.
PubMed Abstract available

HASHIMOTO K, Kaira K, Kawasaki T, Yamaguchi O, et al
Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
Lung Cancer. 2019 Nov 25. pii: S0169-5002(19)30744.
PubMed

ANDERSEN BL, Valentine TR, Lo SB, Carbone DP, et al
Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms.
Lung Cancer. 2019 Nov 21. pii: S0169-5002(19)30729.
PubMed Abstract available

MORITA R, Okishio K, Shimizu J, Saito H, et al
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Lung Cancer. 2019;140:8-18.
PubMed Abstract available

ICHIHARA E, Harada D, Inoue K, Sato K, et al
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Lung Cancer. 2019;139:140-145.
PubMed Abstract available

PRUIS MA, Geurts-Giele WRR, von der TJH, Meijssen IC, et al
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Lung Cancer. 2019;140:46-54.
PubMed Abstract available

BEAU-FALLER M, Pencreach E, Leduc C, Blons H, et al
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the
Lung Cancer. 2019;140:19-26.
PubMed Abstract available

TENDLER S, Holmqvist M, Wagenius G, Lewensohn R, et al
Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study.
Lung Cancer. 2019;139:111-117.
PubMed Abstract available

GIAJ-LEVRA N, Giaj Levra M, Berghmans T, Novello S, et al
Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?
Lung Cancer. 2019 Nov 13. pii: S0169-5002(19)30719.
PubMed

CONG M, Feng H, Ren JL, Xu Q, et al
Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer.
Lung Cancer. 2019;139:73-79.
PubMed Abstract available

LI T, Zhang F, Wu Z, Cui L, et al
PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Lung Cancer. 2019;139:146-150.
PubMed Abstract available

GERBER DE, Camidge DR, Morgensztern D, Cetnar J, et al
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Lung Cancer. 2019;139:60-67.
PubMed Abstract available

TAKEDA M, Sakai K, Hayashi H, Tanaka K, et al
Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Lung Cancer. 2019;139:28-34.
PubMed Abstract available

GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
Erratum to "Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme" [Lung Cancer 134 (August) (2019) 66-71].
Lung Cancer. 2019 Nov 2. pii: S0169-5002(19)30677.
PubMed

MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Lung Cancer. 2019;139:80-88.
PubMed Abstract available

BALATA H, Traverse-Healy L, Blandin-Knight S, Armitage C, et al
Attending community-based lung cancer screening influences smoking behaviour in deprived populations.
Lung Cancer. 2019;139:41-46.
PubMed Abstract available

October 2019

REALE ML, De Luca E, Lombardi P, Marandino L, et al
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
Lung Cancer. 2019;139:47-54.
PubMed Abstract available

ZHANG D, Zhang Y, Huang Y, Kong L, et al
Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Lung Cancer. 2019;139:18-21.
PubMed Abstract available

DREVET G, Duruisseaux M, Maury JM, Benjamin R, et al
Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience.
Lung Cancer. 2019;139:55-59.
PubMed Abstract available

KATAOKA Y, Yamamoto Y, Otsuki T, Kaku S, et al
Corrigendum to "External validation of prognostic indices for overall survival of malignant pleural mesothelioma" [Lung Cancer 113 (November) (2017) 88-92].
Lung Cancer. 2019 Oct 23. pii: S0169-5002(19)30678.
PubMed

MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
Lung Cancer. 2019;139:185-194.
PubMed Abstract available

EICHHORN F, Klotz LV, Muley T, Kobinger S, et al
Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis.
Lung Cancer. 2019;138:95-101.
PubMed Abstract available

THOMPSON JC, Hwang WT, Davis C, Deshpande C, et al
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Lung Cancer. 2019;139:1-8.
PubMed Abstract available

TSUKITA Y, Inoue A, Sugawara S, Kuyama S, et al
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Lung Cancer. 2019;139:89-93.
PubMed Abstract available

SHE L, Hu H, Liao M, Xia X, et al
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Lung Cancer. 2019;138:88-94.
PubMed Abstract available

PULITI D, Mascalchi M, Carozzi FM, Carrozzi L, et al
Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors.
Lung Cancer. 2019;138:72-78.
PubMed Abstract available

OU SI, Gadgeel SM, Barlesi F, Yang JC, et al
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
Lung Cancer. 2019;139:22-27.
PubMed Abstract available

NAITO T, Udagawa H, Umemura S, Sakai T, et al
Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Lung Cancer. 2019;138:35-42.
PubMed Abstract available

PEROL M, Pavlakis N, Levchenko E, Platania M, et al
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Lung Cancer. 2019;138:79-87.
PubMed Abstract available

KHORRAMI M, Jain P, Bera K, Alilou M, et al
Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9].
Lung Cancer. 2019;136:156.
PubMed

BAR J, Ofek E, Barshack I, Gottfried T, et al
Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
Lung Cancer. 2019;138:109-115.
PubMed Abstract available

September 2019

ASAHINA H, Oizumi S, Takamura K, Harada T, et al
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Lung Cancer. 2019;138:65-71.
PubMed Abstract available

MEHLMAN C, Cadranel J, Rousseau-Bussac G, Lacave R, et al
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Lung Cancer. 2019;137:149-156.
PubMed Abstract available

STAMATIS G, Leschber G, Schwarz B, Brintrup DL, et al
Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2cm, stage IA (7th edition of TNM staging
Lung Cancer. 2019;138:19-26.
PubMed Abstract available

PARK SY, Byun GE, Lee CY, Lee JG, et al
Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.
Lung Cancer. 2019;138:1-5.
PubMed Abstract available

GELATTI ACZ, Drilon A, Santini FC
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Lung Cancer. 2019;137:113-122.
PubMed Abstract available

TERAMOTO K, Igarashi T, Kataoka Y, Ishida M, et al
Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Lung Cancer. 2019;137:56-63.
PubMed Abstract available

YOSHIMURA A, Yamada T, Miyagawa-Hayashino A, Sonobe Y, et al
Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
Lung Cancer. 2019;137:108-112.
PubMed Abstract available

AGER BJ, Wells SM, Gruhl JD, Stoddard GJ, et al
Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer.
Lung Cancer. 2019;138:6-12.
PubMed Abstract available

KADOURI L, Rottenberg Y, Zick A, Hamburger T, et al
Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Lung Cancer. 2019;137:48-51.
PubMed Abstract available

GALLI G, De Toma A, Pagani F, Randon G, et al
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Lung Cancer. 2019;137:38-42.
PubMed Abstract available

GUIBERT N, Jones G, Beeler JF, Plagnol V, et al
Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Lung Cancer. 2019;137:1-6.
PubMed Abstract available

BODOR JN, Feliciano JL, Edelman MJ
Corrigendum to "Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation" [Lung Cancer 135 (September) (2019) 16-20].
Lung Cancer. 2019 Sep 5. pii: S0169-5002(19)30616.
PubMed

LAN S, Li H, Liu Y, Ma L, et al
Erratum to "Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer" [Lung Cancer 132 (June) (2019) 154-156].
Lung Cancer. 2019 Sep 4. pii: S0169-5002(19)30622.
PubMed

BESSE B, Barlesi F, Demedts I, Fuentes Pradera J, et al
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Lung Cancer. 2019;137:136-143.
PubMed Abstract available

FRASER I, Lefresne S, Regan J, Berthelet E, et al
Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis.
Lung Cancer. 2019;135:97-103.
PubMed Abstract available

HOJBJERG JA, Ebert EBF, Clement MS, Winther-Larsen A, et al
Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Lung Cancer. 2019;135:92-96.
PubMed Abstract available

CAPIZZI E, Dall'Olio FG, Gruppioni E, Sperandi F, et al
Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Lung Cancer. 2019;135:88-91.
PubMed Abstract available

HOPKINS RJ, Ko J, Gamble GD, Young RP, et al
Airflow limitation and survival after surgery for non-small cell lung cancer: Results from a systematic review and lung cancer screening trial (NLST-ACRIN sub-study).
Lung Cancer. 2019;135:80-87.
PubMed Abstract available

KIM DW, Lee DH, Han JY, Lee J, et al
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
Lung Cancer. 2019;135:66-72.
PubMed Abstract available

GUO J, Wang X, Wang Y, Wang L, et al
A promising role of interferon regulatory factor 5 as an early warning biomarker for the development of human non-small cell lung cancer.
Lung Cancer. 2019;135:47-55.
PubMed Abstract available

MESSARITAKIS I, Nikolaou M, Koinis F, Politaki E, et al
Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Lung Cancer. 2019;135:33-39.
PubMed Abstract available

CADHAM CJ, Jayasekera JC, Advani SM, Fallon SJ, et al
Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis.
Lung Cancer. 2019;135:205-216.
PubMed Abstract available

GRIESINGER F, Korol EE, Kayaniyil S, Varol N, et al
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Lung Cancer. 2019;135:196-204.
PubMed Abstract available

NOSAKI K, Saka H, Hosomi Y, Baas P, et al
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Lung Cancer. 2019;135:188-195.
PubMed Abstract available

HEINEMAN DJ, Hoeijmakers F, Beck N, Dickhoff C, et al
Impact of health care organization on surgical lung cancer care.
Lung Cancer. 2019;135:181-187.
PubMed Abstract available

YOKOYAMA T, Yoshioka H, Fujimoto D, Demura Y, et al
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Lung Cancer. 2019;135:175-180.
PubMed Abstract available

ISLA D, De Las Penas R, Insa A, Marse R, et al
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Lung Cancer. 2019;135:161-168.
PubMed Abstract available

BODOR JN, Feliciano JL, Edelman MJ
Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation.
Lung Cancer. 2019;135:16-20.
PubMed Abstract available

ALCARAZ J, Carrasco JL, Millares L, Luis IC, et al
Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.
Lung Cancer. 2019;135:151-160.
PubMed Abstract available

UDAGAWA H, Akamatsu H, Tanaka K, Takeda M, et al
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Lung Cancer. 2019;135:145-150.
PubMed Abstract available

ZHANG L, Pu D, Liu D, Wang Y, et al
Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.
Lung Cancer. 2019;135:130-137.
PubMed Abstract available

RUDNICKA J, Kowalkowski T, Buszewski B
Searching for selected VOCs in human breath samples as potential markers of lung cancer.
Lung Cancer. 2019;135:123-129.
PubMed Abstract available

NOOR ZS, Goldman JW, Lawler WE, Telivala B, et al
Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
Lung Cancer. 2019;135:104-109.
PubMed Abstract available

KHORRAMI M, Jain P, Bera K, Alilou M, et al
Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.
Lung Cancer. 2019;135:1-9.
PubMed Abstract available

August 2019

SUMITOMO R, Hirai T, Fujita M, Murakami H, et al
PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Lung Cancer. 2019;136:136-144.
PubMed Abstract available

KIM YJ, Keam B, Ock CY, Song S, et al
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Lung Cancer. 2019;136:122-128.
PubMed Abstract available

BHANDARI S, Tripathi P, Pham D, Pinkston C, et al
Performance of community-based lung cancer screening program in a Histoplasma endemic region.
Lung Cancer. 2019;136:102-104.
PubMed Abstract available

AREDO JV, Padda SK, Kunder CA, Han SS, et al
Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
Lung Cancer. 2019 Aug 26. pii: S0169-5002(19)30621.
PubMed

ZHOU K, Jiang C, Li Q
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Lung Cancer. 2019;136:98-101.
PubMed Abstract available

WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38].
Lung Cancer. 2019 Aug 24. pii: S0169-5002(19)30617.
PubMed

YOON DW, Shin DW, Cho JH, Yang JH, et al
Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients.
Lung Cancer. 2019;136:115-121.
PubMed Abstract available

OU SI, Cui J, Schrock AB, Goldberg ME, et al
Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-
Lung Cancer. 2019 Aug 22. pii: S0169-5002(19)30614.
PubMed

TAY RY, Heigener D, Reck M, Califano R, et al
Immune checkpoint blockade in small cell lung cancer.
Lung Cancer. 2019;137:31-37.
PubMed Abstract available

MAYMANI H, Hess K, Groisberg R, Hong DS, et al
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].
Lung Cancer. 2019 Aug 21. pii: S0169-5002(19)30618.
PubMed

JIN J, Gan Y, Liu H, Wang Z, et al
Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation.
Lung Cancer. 2019;136:129-135.
PubMed Abstract available

HE Y, Jia K, Dziadziuszko R, Zhao S, et al
Galectin-9 in non-small cell lung cancer.
Lung Cancer. 2019;136:80-85.
PubMed Abstract available

SHOJI F, Takeoka H, Kozuma Y, Toyokawa G, et al
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Lung Cancer. 2019;136:45-51.
PubMed Abstract available

GAUVAIN C, Vauleon E, Chouaid C, Le Rhun E, et al
Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].
Lung Cancer. 2019 Aug 14. pii: S0169-5002(18)30595.
PubMed

MORGENSZTERN D, Karaseva N, Felip E, Delgado I, et al
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
Lung Cancer. 2019;136:74-79.
PubMed Abstract available

VILLARUZ LC, Cobo M, Syrigos K, Mavroudis D, et al
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Lung Cancer. 2019;136:52-56.
PubMed Abstract available

DESCOURT R, Perol M, Rousseau-Bussac G, Planchard D, et al
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Lung Cancer. 2019;136:109-114.
PubMed Abstract available

LEE GJ, Lee H, Woo IS, Kim T, et al
Erratum to "High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors" [Lung Cancer 132 (June) (2019) 9-16].
Lung Cancer. 2019 Aug 13. pii: S0169-5002(19)30554.
PubMed

LEVY A, Hendriks LEL, Le Pechoux C, Falk S, et al
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.
Lung Cancer. 2019;136:145-147.
PubMed Abstract available

MURTHY V, Katzman DP, Tsay JJ, Bessich JL, et al
Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
Lung Cancer. 2019;137:94-99.
PubMed Abstract available

WEN J, Chen J, Fan M
Comment on the article titled "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
Lung Cancer. 2019 Aug 12. pii: S0169-5002(19)30568.
PubMed

RAJADURAI P, Cheah PL, How SH, Liam CK, et al
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Lung Cancer. 2019;136:65-73.
PubMed Abstract available

CHENG H, Li XJ, Wang XJ, Chen ZW, et al
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Lung Cancer. 2019;137:7-13.
PubMed Abstract available

MAISONNEUVE P, Iavicoli S, Veronesi G
Response to comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
Lung Cancer. 2019 Aug 4. pii: S0169-5002(19)30574.
PubMed

TANG W, Li X, Xie X, Sun X, et al
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Lung Cancer. 2019;136:6-14.
PubMed Abstract available

HARAGAN A, Field JK, Davies MPA, Escriu C, et al
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Lung Cancer. 2019;134:79-84.
PubMed Abstract available

ZUGAZAGOITIA J, Gomez-Rueda A, Jantus-Lewintre E, Isla D, et al
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Lung Cancer. 2019;134:72-78.
PubMed Abstract available

GHIMIRE B, Maroni R, Vulkan D, Shah Z, et al
Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.
Lung Cancer. 2019;134:66-71.
PubMed Abstract available

BOUSEMA JE, van Dorp M, Hoeijmakers F, Huijbregts IA, et al
Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis.
Lung Cancer. 2019;134:52-58.
PubMed Abstract available

HELLYER JA, Stehr H, Das M, Padda SK, et al
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Lung Cancer. 2019;134:42-45.
PubMed Abstract available

VAN DE VEN M, Retel VP, Koffijberg H, van Harten WH, et al
Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.
Lung Cancer. 2019;134:34-41.
PubMed Abstract available

MELOSKY B, Juergens R, McLeod D, Leighl N, et al
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Lung Cancer. 2019;134:259-267.
PubMed Abstract available

BOADA M, Guzman R, Montesinos M, Libreros A, et al
UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY.
Lung Cancer. 2019;134:254-258.
PubMed Abstract available

BALATA H, Evison M, Sharman A, Crosbie P, et al
CT screening for lung cancer: Are we ready to implement in Europe?
Lung Cancer. 2019;134:25-33.
PubMed Abstract available

ACKERMANN CJ, Reck M, Paz-Ares L, Barlesi F, et al
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
Lung Cancer. 2019;134:245-253.
PubMed Abstract available

VANNITAMBY A, Hendry S, Irving L, Steinfort D, et al
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
Lung Cancer. 2019;134:233-237.
PubMed Abstract available

FRANCAVIGLIA I, Magliacane G, Lazzari C, Grassini G, et al
Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Lung Cancer. 2019;134:225-232.
PubMed Abstract available

LIU Z, Liang H, Lin J, Cai X, et al
The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.
Lung Cancer. 2019;134:218-224.
PubMed Abstract available

CAPELLETTO E, Migliorino MR, Morabito A, Chiari R, et al
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
Lung Cancer. 2019;134:210-217.
PubMed Abstract available

YOSHIMURA K, Inoue Y, Karayama M, Tsuchiya K, et al
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Lung Cancer. 2019;134:202-209.
PubMed Abstract available

DING PN, Becker TM, Bray VJ, Chua W, et al
The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Lung Cancer. 2019;134:187-193.
PubMed Abstract available

KASAHARA N, Kaira K, Yamaguchi K, Masubuchi H, et al
Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
Lung Cancer. 2019;134:180-186.
PubMed Abstract available

DIETEL M, Savelov N, Salanova R, Micke P, et al
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Lung Cancer. 2019;134:174-179.
PubMed Abstract available

OWEN DH, Williams TM, Bertino EM, Mo X, et al
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Lung Cancer. 2019;134:167-173.
PubMed Abstract available

TAN KS
Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer.
Lung Cancer. 2019;134:16-24.
PubMed Abstract available

HYUN MH, Lee ES, Eo JS, Kim S, et al
Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
Lung Cancer. 2019;134:158-166.
PubMed Abstract available

KIM H, Goo JM, Paeng JC, Kim YT, et al
Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification.
Lung Cancer. 2019;134:151-157.
PubMed Abstract available

MANJUNATH Y, Upparahalli SV, Suvilesh KN, Avella DM, et al
Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
Lung Cancer. 2019;134:147-150.
PubMed Abstract available

GIBSON AJW, Li H, D'Silva A, Elegbede AA, et al
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
Lung Cancer. 2019;134:141-146.
PubMed Abstract available

DAFNI U, Tsourti Z, Vervita K, Peters S, et al
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Lung Cancer. 2019;134:127-140.
PubMed Abstract available

SANTO A, Pilotto S, Galetta D, Grossi F, et al
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.
Lung Cancer. 2019;134:121-126.
PubMed Abstract available

ZHANG B, Niu X, Zhang Q, Wang C, et al
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Lung Cancer. 2019;134:108-116.
PubMed Abstract available

NAKAMURA H, Sugano M, Miyashita T, Hashimoto H, et al
Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells.
Lung Cancer. 2019;134:100-107.
PubMed Abstract available

HAYASHI H, Iihara H, Hirose C, Fukuda Y, et al
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
Lung Cancer. 2019;134:1-6.
PubMed Abstract available

MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
Corrigendum to "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos" [Lung Cancer, 131 (May) (2019) 23-30].
Lung Cancer. 2019;134:279.
PubMed

CHOE EA, Cha YJ, Kim JH, Pyo KH, et al
Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
Lung Cancer. 2019;136:30-36.
PubMed Abstract available

WANG G, Ionescu DN, Lee CH, Hiruki T, et al
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Lung Cancer. 2019;136:1-5.
PubMed Abstract available

July 2019

GRONDAHL V, Binderup T, Langer SW, Petersen RH, et al
Erratum to "Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence" [Lung Cancer 132 (June) (2019) 141-149].
Lung Cancer. 2019 Jul 31. pii: S0169-5002(19)30561.
PubMed

BARBONE F, Barbiero F, Fasola G
Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
Lung Cancer. 2019 Jul 27. pii: S0169-5002(19)30564.
PubMed

WANG X, Leader JK, Wang R, Wilson D, et al
Erratum to "Vasculature surrounding a nodule: A novel lung cancer biomarker" [Lung Cancer 114 (December) (2017) 38-43].
Lung Cancer. 2019 Jul 26. pii: S0169-5002(19)30560.
PubMed

SUBRAMANIAN J, Fernandes AW, Laliberte F, Pavilack M, et al
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Lung Cancer. 2019;138:131-138.
PubMed Abstract available

STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
Corrigendum to "Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study" [Lung Cancer 130 (2019) (April) 216-225].
Lung Cancer. 2019 Jul 22. pii: S0169-5002(19)30555.
PubMed

AWAD MM, Leonardi GC, Kravets S, Dahlberg SE, et al
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Lung Cancer. 2019;133:96-102.
PubMed Abstract available

PETERS S, Felip E, Dafni U, Belka C, et al
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Lung Cancer. 2019;133:83-87.
PubMed Abstract available

LI X, Zhang C, Sun Z, Yang F, et al
Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
Lung Cancer. 2019;133:75-82.
PubMed Abstract available

TSAKONAS G, Botling J, Micke P, Rivard C, et al
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.
Lung Cancer. 2019;133:69-74.
PubMed Abstract available

MORABITO A, Piccirillo MC, Maione P, Luciani A, et al
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.
Lung Cancer. 2019;133:62-68.
PubMed Abstract available

DIMOU A, Bamias A, Gogas H, Syrigos K, et al
Inhibition of the Hedgehog pathway in lung cancer.
Lung Cancer. 2019;133:56-61.
PubMed Abstract available

MELOSKY B, Bradbury P, Tu D, Florescu M, et al
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group
Lung Cancer. 2019;133:48-55.
PubMed Abstract available

SAKIN A, Sahin S, Yasar N, Demir C, et al
Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
Lung Cancer. 2019;133:38-44.
PubMed Abstract available

LOWENSTEIN M, Vijayaraghavan M, Burke NJ, Karliner L, et al
Real-world lung cancer screening decision-making: Barriers and facilitators.
Lung Cancer. 2019;133:32-37.
PubMed Abstract available

AREDO JV, Padda SK, Kunder CA, Han SS, et al
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Lung Cancer. 2019;133:144-150.
PubMed Abstract available

SHINDE A, Horne ZD, Li R, Glaser S, et al
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Lung Cancer. 2019;133:136-143.
PubMed Abstract available

DEGENS JHRJ, Sanders KJC, de Jong EEC, Groen HJM, et al
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
Lung Cancer. 2019;133:130-135.
PubMed Abstract available

ROMERO-VIELVA L, Viteri S, Moya-Horno I, Toscas JI, et al
Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
Lung Cancer. 2019;133:117-122.
PubMed Abstract available

KSIENSKI D, Wai ES, Croteau N, Freeman AT, et al
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Lung Cancer. 2019;133:110-116.
PubMed Abstract available

GAYE E, Geier M, Bore P, Guilloique M, et al
Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
Lung Cancer. 2019;133:1-3.
PubMed Abstract available

June 2019

PARDO-CABELLO AJ, Manzano-Gamero V
Small cell lung cancer elevates procalcitonin levels in the absence of infection.
Lung Cancer. 2019 Jun 17. pii: S0169-5002(19)30511.
PubMed

FUJIMOTO D, Yomota M, Sekine A, Morita M, et al
Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Lung Cancer. 2019 Jun 3. pii: S0169-5002(19)30494.
PubMed Abstract available

YOO JK, Lee JM, Kang SH, Jeon SH, et al
The novel microRNA hsa-miR-CHA1 regulates cell proliferation and apoptosis in human lung cancer by targeting XIAP.
Lung Cancer. 2019;132:99-106.
PubMed Abstract available

SUH CH, Kim KW, Pyo J, Hatabu H, et al
The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
Lung Cancer. 2019;132:79-86.
PubMed Abstract available

GALLI G, Triulzi T, Proto C, Signorelli D, et al
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
Lung Cancer. 2019;132:72-78.
PubMed Abstract available

ASSOUN S, Theou-Anton N, Nguenang M, Cazes A, et al
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Lung Cancer. 2019;132:65-71.
PubMed Abstract available

ICHIHARA E, Hotta K, Ninomiya K, Kubo T, et al
Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
Lung Cancer. 2019;132:54-58.
PubMed Abstract available

CUI S, Ni Y, Zhao Y, Li Z, et al
Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Lung Cancer. 2019;132:45-53.
PubMed Abstract available

WANG H, Agulnik J, Kasymjanova G, Fiset PO, et al
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Lung Cancer. 2019;132:36-38.
PubMed Abstract available

PLATANIA M, Pasini F, Porcu L, Boeri M, et al
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
Lung Cancer. 2019;132:17-23.
PubMed Abstract available

VAD-NIELSEN J, Gammelgaard KR, Daugaard TF, Nielsen AL, et al
Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
Lung Cancer. 2019;132:132-140.
PubMed Abstract available

PARK K, Bennouna J, Boyer M, Hida T, et al
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
Lung Cancer. 2019;132:126-131.
PubMed Abstract available

MINNITI G, Scaringi C, Lanzetta G, Anzellini D, et al
Comparative effectiveness of multi-fraction stereotactic radiosurgery for surgically resected or intact large brain metastases from non-small-cell lung cancer (NSCLC).
Lung Cancer. 2019;132:119-125.
PubMed Abstract available

LIANG F, Wu C, Gu H, Zhu M, et al
Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening.
Lung Cancer. 2019;132:114-118.
PubMed Abstract available

OYANAGI J, Koh Y, Sato K, Mori K, et al
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Lung Cancer. 2019;132:107-113.
PubMed Abstract available

FUKUDA M, Kitazaki T, Ogawara D, Ichiki M, et al
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Lung Cancer. 2019;132:1-8.
PubMed Abstract available

SONG T, Jiang L, Lin Y
Comment on: 'Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas'.
Lung Cancer. 2019;132:150.
PubMed

HSIEH MS, Lin MW
Response to comment on: "Correlation of Tumor Spread through Air Spaces and Clinicopathological Characteristics in Surgically Resected Lung Adenocarcinomas."
Lung Cancer. 2019;132:151.
PubMed

May 2019

TAKANO N, Ariyasu R, Koyama J, Sonoda T, et al
Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.
Lung Cancer. 2019;131:69-77.
PubMed Abstract available

LIN C, Shi X, Yang S, Zhao J, et al
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
Lung Cancer. 2019;131:62-68.
PubMed Abstract available

PEROL M, Winfree KB, Cuyun Carter G, Lin Cui Z, et al
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Lung Cancer. 2019;131:6-13.
PubMed Abstract available

SULLIVAN DR, Eden KB, Dieckmann NF, Golden SE, et al
Understanding patients' values and preferences regarding early stage lung cancer treatment decision making.
Lung Cancer. 2019;131:47-57.
PubMed Abstract available

WILLEN L, Berglund A, Bergstrom S, Bergqvist M, et al
Educational level and management and outcomes in non-small cell lung cancer. A nationwide population-based study.
Lung Cancer. 2019;131:40-46.
PubMed Abstract available

VAYR F, Savall F, Bigay-Game L, Soulat JM, et al
Lung cancer survivors and employment: A systematic review.
Lung Cancer. 2019;131:31-39.
PubMed Abstract available

MAISONNEUVE P, Rampinelli C, Bertolotti R, Misotti A, et al
Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos.
Lung Cancer. 2019;131:23-30.
PubMed Abstract available

YAN SX, Qureshi MM, Dyer M, Truong MT, et al
Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Lung Cancer. 2019;131:147-153.
PubMed Abstract available

YIN K, Li YS, Zheng MM, Jiang BY, et al
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
Lung Cancer. 2019;131:134-138.
PubMed Abstract available

LATTUCA-TRUC M, Timsit JF, Levra MG, Ruckly S, et al
Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017.
Lung Cancer. 2019;131:122-127.
PubMed Abstract available

YAMADA T, Ohta K, Motooka Y, Fujino K, et al
Significance of Tsukushi in lung cancer.
Lung Cancer. 2019;131:104-111.
PubMed Abstract available

CHRISTENSEN NL, Dalton S, Ravn J, Christensen J, et al
Treatment, no treatment and early death in Danish stage I lung cancer patients.
Lung Cancer. 2019;131:1-5.
PubMed Abstract available

GAN CT, Verschuuren E, van de Bij W, Van De Wauwer C, et al
Comment on: Synchronous multiple non-small cell lung cancers in an allograft lung recipient.
Lung Cancer. 2019;131:154.
PubMed

PUJOL JL, Bommart S, Pujol P
Response to comment on: 'Synchronous multiple non-small cell lung cancers in an allograft lung recipient'.
Lung Cancer. 2019;131:155-156.
PubMed

April 2019

LAN S, Li H, Liu Y, Ma L, et al
Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer.
Lung Cancer. 2019 Apr 28. pii: S0169-5002(19)30426.
PubMed

FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168].
Lung Cancer. 2019 Apr 25. pii: S0169-5002(19)30398.
PubMed

NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
Lung Cancer. 2019 Apr 24. pii: S0169-5002(19)30399.
PubMed

WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lu
Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30397.
PubMed

HARRIS EJA, Musk AW, DeKlerk N, Brims FJH, et al
Correspondence regarding "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos".
Lung Cancer. 2019 Apr 20. pii: S0169-5002(19)30417.
PubMed

HAQUE W, Verma V, Butler EB, Teh BS, et al
Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
Lung Cancer. 2019;130:93-100.
PubMed Abstract available

LEE K, Kim Y, Jung HA, Lee SH, et al
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
Lung Cancer. 2019;130:87-92.
PubMed Abstract available

JIANG T, Bai Y, Zhou F, Li W, et al
Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
Lung Cancer. 2019;130:76-83.
PubMed Abstract available

ARRIETA O, Barron F, Maldonado F, Cabrera L, et al
Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
Lung Cancer. 2019;130:67-75.
PubMed Abstract available

GUBENS MA, Sequist LV, Stevenson JP, Powell SF, et al
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Lung Cancer. 2019;130:59-66.
PubMed Abstract available

LA FLEUR L, Falk-Sorqvist E, Smeds P, Berglund A, et al
Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
Lung Cancer. 2019;130:50-58.
PubMed Abstract available

YONESHIMA Y, Tanaka K, Shiraishi Y, Hata K, et al
Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
Lung Cancer. 2019;130:5-9.
PubMed Abstract available

PERUMAL E, So Youn K, Sun S, Seung-Hyun J, et al
PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of beta-catenin and snail/slug in non-small cell lung carcinoma cells.
Lung Cancer. 2019;130:25-34.
PubMed Abstract available

STEFFENS CC, Elender C, Hutzschenreuter U, Dille S, et al
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Lung Cancer. 2019;130:216-225.
PubMed Abstract available

LUO Q, Steinberg J, O'Connell DL, Yu XQ, et al
Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?
Lung Cancer. 2019;130:208-215.
PubMed Abstract available

WU YL, Zhou C, Lu S, Qin S, et al
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Lung Cancer. 2019;130:18-24.
PubMed Abstract available

CARNEIRO-LOBO TC, Scalabrini LC, Magalhaes LDS, Cardeal LB, et al
IKKbeta targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Lung Cancer. 2019;130:169-178.
PubMed Abstract available

FOSTER CC, Rusthoven CG, Sher DJ, Feldman L, et al
Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
Lung Cancer. 2019;130:162-168.
PubMed Abstract available

SAKATA Y, Kawamura K, Ichikado K, Shingu N, et al
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Lung Cancer. 2019;130:159-161.
PubMed Abstract available

BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
Patient reported outcome data as performance indicators in surgically treated lung cancer patients.
Lung Cancer. 2019;130:143-148.
PubMed Abstract available

COSTANTINI A, Fallet V, Corny J, Friard S, et al
Nivolumab-refractory patients with advanced non-small-cell lung cancer.
Lung Cancer. 2019;130:128-134.
PubMed Abstract available

MELTZER LR, Unrod M, Simmons VN, Brandon KO, et al
Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening.
Lung Cancer. 2019;130:121-127.
PubMed Abstract available

GEERSE OP, Brandenbarg D, Kerstjens HAM, Berendsen AJ, et al
The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer.
Lung Cancer. 2019;130:101-107.
PubMed Abstract available

ZHAO S, Gao G, Li W, Li X, et al
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
Lung Cancer. 2019;130:10-17.
PubMed Abstract available

ZHOU K, Zhou J, Huang J, Zhang N, et al
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
Lung Cancer. 2019;130:1-4.
PubMed Abstract available

March 2019

HU SY, Hsieh MS, Hsu HH, Tsai TM, et al
Corrigendum to "Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas" [Lung Cancer 126 (2018) 189-193].
Lung Cancer. 2019 Mar 13. pii: S0169-5002(19)30349.
PubMed

ONO A, Isaka M, Serizawa M, Omae K, et al
Corrigendum to "Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer" [Lung Cancer 128 (2019) 152-157].
Lung Cancer. 2019 Mar 12. pii: S0169-5002(19)30350.
PubMed

BRAVACCINI S
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?
Lung Cancer. 2019 Mar 11. pii: S0169-5002(19)30355.
PubMed Abstract available

UBERALL I, Gachechiladze M, Joerger M, Andel J, et al
Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer.
Lung Cancer. 2019;129:85-91.
PubMed Abstract available

MENDOZA DP, Dagogo-Jack I, Chen T, Padole A, et al
Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.
Lung Cancer. 2019;129:80-84.
PubMed Abstract available

HEILBRONER SP, Xanthopoulos EP, Buono D, Huang Y, et al
Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer.
Lung Cancer. 2019;129:8-15.
PubMed Abstract available

TUNALI I, Gray JE, Qi J, Abdalah M, et al
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
Lung Cancer. 2019;129:75-79.
PubMed Abstract available

ZHENG X, Zhang G, Li P, Zhang M, et al
Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
Lung Cancer. 2019;129:72-74.
PubMed Abstract available

ANDRATSCHKE N, Kraft J, Nieder C, Tay R, et al
Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
Lung Cancer. 2019;129:63-71.
PubMed Abstract available

WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
Lung Cancer. 2019;129:55-62.
PubMed Abstract available

KOH YW, Lee SJ, Han JH, Haam S, et al
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Lung Cancer. 2019;129:41-47.
PubMed Abstract available

CRINO L, Bronte G, Bidoli P, Cravero P, et al
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
Lung Cancer. 2019;129:35-40.
PubMed Abstract available

GEMINE RE, Ghosal R, Collier G, Parry D, et al
Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer.
Lung Cancer. 2019;129:1-7.
PubMed Abstract available

LIU Y, Liu T, Li N, Wang T, et al
Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Lung Cancer. 2019;129:92-94.
PubMed Abstract available

BO L, Li C, Pan L, Wang H, et al
Diagnosing a solitary pulmonary nodule using multiple bronchoscopic guided technologies: A prospective randomized study.
Lung Cancer. 2019;129:48-54.
PubMed Abstract available

YANG B, Lee H, Um SW, Kim K, et al
Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.
Lung Cancer. 2019;129:28-34.
PubMed Abstract available

THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
Hospital lung surgery volume and patient outcomes.
Lung Cancer. 2019;129:22-27.
PubMed Abstract available

ISHIDA H, Shimizu Y, Sakaguchi H, Nitanda H, et al
Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
Lung Cancer. 2019;129:16-21.
PubMed Abstract available

YAMASAKI M, Takenaka T, Matsumoto N, Asaoku H, et al
Primary pulmonary collision tumor comprising squamous cell carcinoma and mucosa-associated lymphoid tissue lymphoma.
Lung Cancer. 2019;129:107-109.
PubMed

February 2019

SHI JF, Wang L, Wu N, Li JL, et al
Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey.
Lung Cancer. 2019;128:91-100.
PubMed Abstract available

HORN L, Bauml J, Forde PM, Davis KL, et al
Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
Lung Cancer. 2019;128:74-90.
PubMed Abstract available

BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study.
Lung Cancer. 2019;128:67-73.
PubMed Abstract available

YAN X, Wang H, Li P, Zhang G, et al
Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Lung Cancer. 2019;128:6-12.
PubMed Abstract available

NIEUWENHUIS L, van den Brandt PA
Nut and peanut butter consumption and the risk of lung cancer and its subtypes: A prospective cohort study.
Lung Cancer. 2019;128:57-66.
PubMed Abstract available

HAMADA K, Irie M, Fujino Y, Hyodo M, et al
Prognostic value of preoperative exercise capacity in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer.
Lung Cancer. 2019;128:47-52.
PubMed Abstract available

ZAMARRON E, Prats E, Tejero E, Pardo P, et al
Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease.
Lung Cancer. 2019;128:40-46.
PubMed Abstract available

MIZUGAKI H, Hamada A, Shibata T, Hosoda F, et al
Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
Lung Cancer. 2019;128:20-25.
PubMed Abstract available

SCHUCHERT MJ, Normolle DP, Awais O, Pennathur A, et al
Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer.
Lung Cancer. 2019;128:145-151.
PubMed Abstract available

CEDILLO JL, Bordas A, Arnalich F, Esteban-Rodriguez I, et al
Anti-tumoral activity of the human-specific duplicated form of alpha7-nicotinic receptor subunit in tobacco-induced lung cancer progression.
Lung Cancer. 2019;128:134-144.
PubMed Abstract available

ABEL S, Hasan S, White R, Schumacher L, et al
Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
Lung Cancer. 2019;128:127-133.
PubMed Abstract available

KOO HJ, Choi CM, Park S, Lee HN, et al
Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea.
Lung Cancer. 2019;128:120-126.
PubMed Abstract available

ITO K, Miura S, Sakaguchi T, Murotani K, et al
The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Lung Cancer. 2019;128:113-119.
PubMed Abstract available

GADGEEL SM, Lukas RV, Goldschmidt J, Conkling P, et al
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Lung Cancer. 2019;128:105-112.
PubMed Abstract available

STEVENS C, Smith SG, Quaife SL, Vrinten C, et al
Interest in lifestyle advice at lung cancer screening: Determinants and preferences.
Lung Cancer. 2019;128:1-5.
PubMed Abstract available

MAUCLET C, Duplaquet F, Pirard L, Rondelet B, et al
Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab.
Lung Cancer. 2019;128:53-56.
PubMed Abstract available

ZHAO S, Li X, Zhao C, Jiang T, et al
Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Lung Cancer. 2019;128:33-39.
PubMed Abstract available

TAKADA K, Kohashi K, Shimokawa M, Haro A, et al
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Lung Cancer. 2019;128:26-32.
PubMed Abstract available

January 2019

HENDRIKS LEL, Dingemans AC
Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?
Lung Cancer. 2019 Jan 30. pii: S0169-5002(19)30297.
PubMed

AULIAC JB, Perol M, Planchard D, Monnet I, et al
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Lung Cancer. 2019;127:96-102.
PubMed Abstract available

YOON HS, Wen W, Long J, Zheng W, et al
Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States.
Lung Cancer. 2019;127:90-95.
PubMed Abstract available

GU X, Zhang Q, Chu YB, Zhao YY, et al
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lung Cancer. 2019;127:84-89.
PubMed Abstract available

HAQUE W, Verma V, Butler EB, Teh BS, et al
Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
Lung Cancer. 2019;127:76-83.
PubMed Abstract available

DOTSON T, Bellinger C, Su J, Hansen K, et al
Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).
Lung Cancer. 2019;127:6-11.
PubMed Abstract available

SAKAI H, Takeda M, Sakai K, Nakamura Y, et al
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Lung Cancer. 2019;127:59-65.
PubMed Abstract available

COUTINHO AD, Shah M, Lunacsek OE, Eaddy M, et al
Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy.
Lung Cancer. 2019;127:53-58.
PubMed Abstract available

CHOUAID C, Bensimon L, Clay E, Millier A, et al
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Lung Cancer. 2019;127:44-52.
PubMed Abstract available

THOMPSON JC, Fan R, Black T, Yu GH, et al
Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
Lung Cancer. 2019;127:25-33.
PubMed Abstract available

YU Y, Ou Q, Wu X, Bao H, et al
Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Lung Cancer. 2019;127:19-24.
PubMed Abstract available

HASEGAWA H, Yasuda H, Hamamoto J, Masuzawa K, et al
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
Lung Cancer. 2019;127:146-152.
PubMed Abstract available

MONSALVE AF, Hoag JR, Resio BJ, Chiu AS, et al
Variable impact of prior cancer history on the survival of lung cancer patients.
Lung Cancer. 2019;127:130-137.
PubMed Abstract available

MURAWSKI M, Walter J, Schwarzkopf L
Assessing the lung cancer comorbidome: An analysis of German claims data.
Lung Cancer. 2019;127:122-129.
PubMed Abstract available

PYO KH, Kim JH, Lee JM, Kim SE, et al
Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Lung Cancer. 2019;127:112-121.
PubMed Abstract available

WU YL, Zhao Q, Deng L, Zhang Y, et al
Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
Lung Cancer. 2019;127:1-5.
PubMed Abstract available

SUH CH, Kim KW, Nishino M
Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis i
Lung Cancer. 2019;127:168.
PubMed

CHAPEL DB, Churg A, Santoni-Rugiu E, Tsujimura T, et al
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Lung Cancer. 2019;127:69-75.
PubMed Abstract available

PARK S, Han J, Sun JM
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor.
Lung Cancer. 2019;127:66-68.
PubMed Abstract available

HSU KH, Huang YH, Tseng JS, Chen KC, et al
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients.
Lung Cancer. 2019;127:37-43.
PubMed Abstract available

ROMESSER PB, Bardash Y, Buonocore D, Chaft JE, et al
Outcomes of Stage III NSCLC with occult primary vs. known primary lesions.
Lung Cancer. 2019;127:34-36.
PubMed Abstract available

MAZZASCHI G, Facchinetti F, Missale G, Canetti D, et al
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Lung Cancer. 2019;127:153-163.
PubMed Abstract available

WU L, Dell'Anno I, Lapidot M, Sekido Y, et al
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
Lung Cancer. 2019;127:138-145.
PubMed Abstract available

ROCA E, Pozzari M, Vermi W, Tovazzi V, et al
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case.
Lung Cancer. 2019;127:12-18.
PubMed Abstract available

HALMOS B, Tan EH, Soo RA, Cadranel J, et al
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).
Lung Cancer. 2019;127:103-111.
PubMed Abstract available

December 2018

LIN YT, Chu CY
Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer.
Lung Cancer. 2018 Dec 31. pii: S0169-5002(18)30730.
PubMed

ONO A, Isaka M, Serizawa M, Omae K, et al
Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
Lung Cancer. 2018 Dec 5. pii: S0169-5002(18)30691.
PubMed Abstract available

CAPIZZI E, Ricci C, Giunchi F, Zagnoni S, et al
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Lung Cancer. 2018;126:9-14.
PubMed Abstract available

UNG MH, MacKenzie TA, Onega TL, Amos CI, et al
Statins associate with improved mortality among patients with certain histological subtypes of lung cancer.
Lung Cancer. 2018;126:89-96.
PubMed Abstract available

KOGA T, Kobayashi Y, Tomizawa K, Suda K, et al
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Lung Cancer. 2018;126:72-79.
PubMed Abstract available

MOREL H, Raynard B, d'Arlhac M, Hauss PA, et al
Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.
Lung Cancer. 2018;126:55-63.
PubMed Abstract available

HASHEMI SADRAEI N, Feng Y, Du L, Fu P, et al
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Lung Cancer. 2018;126:48-54.
PubMed Abstract available

IMAI H, Kaira K, Suzuki K, Anzai M, et al
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Lung Cancer. 2018;126:41-47.
PubMed Abstract available

MEIJER TWH, Peeters WJM, Dubois LJ, van Gisbergen MW, et al
Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer.
Lung Cancer. 2018;126:32-40.
PubMed Abstract available

UDAGAWA H, Umemura S, Murakami I, Mimaki S, et al
Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
Lung Cancer. 2018;126:182-188.
PubMed Abstract available

SCHWYZER M, Ferraro DA, Muehlematter UJ, Curioni-Fontecedro A, et al
Automated detection of lung cancer at ultralow dose PET/CT by deep neural networks - Initial results.
Lung Cancer. 2018;126:170-173.
PubMed Abstract available

ANAI S, Iwama E, Yoneshima Y, Otsubo K, et al
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Lung Cancer. 2018;126:156-161.
PubMed Abstract available

JOHN T, Akamatsu H, Delmonte A, Su WC, et al
EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Lung Cancer. 2018;126:133-138.
PubMed Abstract available

QUIST M, Sommer MS, Vibe-Petersen J, Staerkind MB, et al
Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial.
Lung Cancer. 2018;126:125-132.
PubMed Abstract available

HINDE S, Crilly T, Balata H, Bartlett R, et al
The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot.
Lung Cancer. 2018;126:119-124.
PubMed Abstract available

NG TL, Morgan RL, Patil T, Baron AE, et al
Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Lung Cancer. 2018;126:112-118.
PubMed Abstract available

November 2018

SATO K, Akamatsu H, Murakami E, Sasaki S, et al
Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].
Lung Cancer. 2018 Nov 17. pii: S0169-5002(18)30635.
PubMed

TANAKA I, Morise M, Kodama Y, Matsui A, et al
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.
Lung Cancer. 2018 Nov 14. pii: S0169-5002(18)30645.
PubMed

SUN Z, Sui X, Yang F, Wang J, et al
Effects of primary tumor resection on the survival of patients with stage IV extrathoracic metastatic non-small cell lung cancer: A population-based study.
Lung Cancer. 2018 Nov 13. pii: S0169-5002(18)30639.
PubMed Abstract available

ZHAO B, Zhang W
Reply to the comments on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Lung Cancer. 2018 Nov 12. pii: S0169-5002(18)30638.
PubMed

HANIBUCHI M, Kakiuchi S, Atagi S, Ogushi F, et al
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Lung Cancer. 2018;125:93-99.
PubMed Abstract available

LIU SY, Dong ZY, Wu SP, Xie Z, et al
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Lung Cancer. 2018;125:86-92.
PubMed Abstract available

CHEN K, Yu X, Zhang F, Xu Y, et al
Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
Lung Cancer. 2018;125:8-13.
PubMed Abstract available

COSTA GJ, de Mello MJG, Ferreira CG, Bergmann A, et al
Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data.
Lung Cancer. 2018;125:77-85.
PubMed Abstract available

LUO Q, Yu XQ, Wade S, Caruana M, et al
Lung cancer mortality in Australia: Projected outcomes to 2040.
Lung Cancer. 2018;125:68-76.
PubMed Abstract available

CHECK DK, Albers KB, Uppal KM, Suga JM, et al
Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members.
Lung Cancer. 2018;125:51-56.
PubMed Abstract available

SOTIROPOULOS GP, Dalamaga M, Antonakos G, Marinou I, et al
Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
Lung Cancer. 2018;125:291-299.
PubMed Abstract available

BALATA H, Foden P, Edwards T, Chaturvedi A, et al
Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score.
Lung Cancer. 2018;125:29-34.
PubMed Abstract available

LIN MW, Su KY, Su TJ, Chang CC, et al
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lung Cancer. 2018;125:282-290.
PubMed Abstract available

GADGEEL SM, Stevenson JP, Langer CJ, Gandhi L, et al
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Lung Cancer. 2018;125:273-281.
PubMed Abstract available

ISOBE K, Kaburaki K, Kobayashi H, Sano G, et al
New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia.
Lung Cancer. 2018;125:253-257.
PubMed Abstract available

WANG S, Zhang B, Qian J, Qiao R, et al
Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
Lung Cancer. 2018;125:245-252.
PubMed Abstract available

JEGOU D, Dubois C, Schillemans V, Stordeur S, et al
Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.
Lung Cancer. 2018;125:238-244.
PubMed Abstract available

SAITO T, Tsuta K, Ishida M, Ryota H, et al
Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
Lung Cancer. 2018;125:230-237.
PubMed Abstract available

KORT S, Tiggeloven MM, Brusse-Keizer M, Gerritsen JW, et al
Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis.
Lung Cancer. 2018;125:223-229.
PubMed Abstract available

JIA Y, Li X, Zhao C, Jiang T, et al
Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Lung Cancer. 2018;125:22-28.
PubMed Abstract available

YAMAGUCHI T, Shimizu J, Hasegawa T, Horio Y, et al
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
Lung Cancer. 2018;125:212-217.
PubMed Abstract available

MALHOTRA J, Rotter D, Jabbour SK, Aisner J, et al
Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.
Lung Cancer. 2018;125:205-211.
PubMed Abstract available

YUTAKA Y, Sonobe M, Kawaguchi A, Hamaji M, et al
Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure.
Lung Cancer. 2018;125:192-197.
PubMed Abstract available

KARLSSON T, Kvarnbrink S, Holmlund C, Botling J, et al
LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
Lung Cancer. 2018;125:174-184.
PubMed Abstract available

FROST N, Tessmer A, Schmittel A, van Laak V, et al
Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Lung Cancer. 2018;125:164-173.
PubMed Abstract available

DJUREINOVIC D, Dodig-Crnkovic T, Hellstrom C, Holgersson G, et al
Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
Lung Cancer. 2018;125:157-163.
PubMed Abstract available

CHO JY, Kim J, Lee JS, Kim YJ, et al
Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Lung Cancer. 2018;125:150-156.
PubMed Abstract available

KAWANO Y, Sasaki T, Yamaguchi H, Hirano K, et al
Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Lung Cancer. 2018;125:136-141.
PubMed Abstract available

DEJIMA H, Nakanishi H, Kuroda H, Yoshimura M, et al
Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.
Lung Cancer. 2018;125:128-135.
PubMed Abstract available

MOFFAT J, Hiom S, Kumar HS, Baldwin DR, et al
Lung cancer screening - gaining consensus on next steps - proceedings of a closed workshop in the UK.
Lung Cancer. 2018;125:121-127.
PubMed Abstract available

REN S, Tian Q, Amar N, Yu H, et al
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Lung Cancer. 2018;125:115-120.
PubMed Abstract available

WALTER JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, et al
Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.
Lung Cancer. 2018;125:103-108.
PubMed Abstract available

EZEIFE DA, Kirk V, Chew DS, Nixon NA, et al
Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Lung Cancer. 2018;125:1-7.
PubMed Abstract available

October 2018

LUCCHESI C, Drogat B, Santamaria D, Cousin S, et al
Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer.
Lung Cancer. 2018 Oct 12. pii: S0169-5002(18)30597.
PubMed

ILIE M, Beaulande M, Hamila M, Erb G, et al
Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
Lung Cancer. 2018;124:90-94.
PubMed Abstract available

HARRIS JP, Nwachukwu C, Qian Y, Pollom E, et al
Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.
Lung Cancer. 2018;124:76-85.
PubMed Abstract available

UCHIBORI K, Satouchi M, Sueoka-Aragane N, Urata Y, et al
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Lung Cancer. 2018;124:65-70.
PubMed Abstract available

DE JONG EEC, van Elmpt W, Rizzo S, Colarieti A, et al
Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
Lung Cancer. 2018;124:6-11.
PubMed Abstract available

FERRER I, Zugazagoitia J, Herbertz S, John W, et al
KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Lung Cancer. 2018;124:53-64.
PubMed Abstract available

CHRISTENSEN NL, Lokke A, Dalton SO, Christensen J, et al
Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients.
Lung Cancer. 2018;124:40-44.
PubMed Abstract available

BIRCAN HA, Gurbuz N, Pataer A, Caner A, et al
Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Lung Cancer. 2018;124:31-39.
PubMed Abstract available

LIM SW, Park S, Kim Y, Cho JH, et al
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
Lung Cancer. 2018;124:293-297.
PubMed Abstract available

HASAN S, Renz P, Turrisi A, Colonias A, et al
Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.
Lung Cancer. 2018;124:283-290.
PubMed Abstract available

MESSARITAKIS I, Nikolaou M, Politaki E, Koinis F, et al
Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment.
Lung Cancer. 2018;124:270-278.
PubMed Abstract available

OKAMOTO T, Yano T, Shimokawa M, Takeo S, et al
A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Lung Cancer. 2018;124:255-259.
PubMed Abstract available

GEORGIEVA M, da Silveira Nogueira Lima JP, Aguiar P Jr, de Lima Lopes G Jr, et al
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
Lung Cancer. 2018;124:248-254.
PubMed Abstract available

HASHIMOTO T, Osoegawa A, Takumi Y, Abe M, et al
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
Lung Cancer. 2018;124:241-247.
PubMed Abstract available

JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
Lung Cancer. 2018;124:233-240.
PubMed Abstract available

NAJJAR F, Alammar M, Al-Massarani G, Almalla N, et al
Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer.
Lung Cancer. 2018;124:23-30.
PubMed Abstract available

HSIEH MS, Lee YH, Lin MW, Chen JS, et al
Solitary pulmonary capillary hemangioma: An under-recognized pulmonary lesion mimicking early lung cancer on computed tomography images.
Lung Cancer. 2018;124:227-232.
PubMed Abstract available

MERINO LARA T, Helou J, Poon I, Sahgal A, et al
Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
Lung Cancer. 2018;124:219-226.
PubMed Abstract available

STONE E, Rankin N, Kerr S, Fong K, et al
Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study.
Lung Cancer. 2018;124:199-204.
PubMed Abstract available

HOFER F, Kauczor HU, Stargardt T
Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.
Lung Cancer. 2018;124:189-198.
PubMed Abstract available

SEKINE K, Kanda S, Goto Y, Horinouchi H, et al
Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
Lung Cancer. 2018;124:179-188.
PubMed Abstract available

KANG HN, Choi JW, Shim HS, Kim J, et al
Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
Lung Cancer. 2018;124:168-178.
PubMed Abstract available

CLARK ME, Bedford LE, Young B, Robertson JFR, et al
Lung cancer CT screening: Psychological responses in the presence and absence of pulmonary nodules.
Lung Cancer. 2018;124:160-167.
PubMed Abstract available

SIM WC, Loh CH, Toh GL, Lim CW, et al
Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Lung Cancer. 2018;124:154-159.
PubMed Abstract available

BALATA H, Blandin Knight S, Barber P, Colligan D, et al
Targeted lung cancer screening selects individuals at high risk of cardiovascular disease.
Lung Cancer. 2018;124:148-153.
PubMed Abstract available

LAFITTE C, Etienne-Mastroianni B, Fournel C, Natoli L, et al
Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancer.
Lung Cancer. 2018;124:143-147.
PubMed Abstract available

YAN SX, Qureshi MM, Suzuki K, Dyer M, et al
Definitive treatment patterns and survival in stage II non-small cell lung cancer.
Lung Cancer. 2018;124:135-142.
PubMed Abstract available

DUDNIK E, Bshara E, Grubstein A, Fridel L, et al
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Lung Cancer. 2018;124:117-124.
PubMed Abstract available

GRANGER CL, Irving L, Antippa P, Edbrooke L, et al
CAPACITY: A physical activity self-management program for patients undergoing surgery for lung cancer, a phase I feasibility study.
Lung Cancer. 2018;124:102-109.
PubMed Abstract available

MATYS T, Drury R, David S, Rassl DM, et al
Corrigendum to "Routine preoperative brain CT in resectable non-small cell lung cancer-Ten years experience from a tertiary UK thoracic center" [Lung Cancer 122 (August) (2018) 195-199].
Lung Cancer. 2018 Oct 1. pii: S0169-5002(18)30575.
PubMed

September 2018

XU R, Zhu J
Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Lung Cancer. 2018 Sep 24. pii: S0169-5002(18)30577.
PubMed

XU R, Zhu J
Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Lung Cancer. 2018 Sep 7. pii: S0169-5002(18)30559.
PubMed

GARON EB, Siegfried JM, Stabile LP, Young PA, et al
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Lung Cancer. 2018;123:91-98.
PubMed Abstract available

SCILLA KA, Zandberg DP, Bentzen SM, Mainor C, et al
Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Lung Cancer. 2018;123:87-90.
PubMed Abstract available

VUONG HG, Ho ATN, Altibi AMA, Nakazawa T, et al
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Lung Cancer. 2018;123:76-82.
PubMed Abstract available

JIAO XD, Qin BD, You P, Cai J, et al
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Lung Cancer. 2018;123:70-75.
PubMed Abstract available

SONG Y, Zhou Q, Zhang X, Chen GY, et al
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
Lung Cancer. 2018;123:7-13.
PubMed Abstract available

SUH CH, Park HS, Kim KW, Pyo J, et al
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Lung Cancer. 2018;123:60-69.
PubMed Abstract available

LU S, Kong H, Hou Y, Ge D, et al
Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer.
Lung Cancer. 2018;123:44-51.
PubMed Abstract available

LIU F, Liu Y, Liu X, Mao K, et al
Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
Lung Cancer. 2018;123:36-43.
PubMed Abstract available

TAIRA N, Atsumi E, Nakachi S, Takamatsu R, et al
Comparison of GLUT-1, SGLT-1, and SGLT-2 expression in false-negative and true-positive lymph nodes during the (18)F-FDG PET/CT mediastinal nodal staging of non-small cell lung cancer.
Lung Cancer. 2018;123:30-35.
PubMed Abstract available

JAO K, Tomasini P, Kamel-Reid S, Korpanty GJ, et al
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Lung Cancer. 2018;123:22-29.
PubMed Abstract available

HU X, Hay JW
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
Lung Cancer. 2018;123:166-171.
PubMed Abstract available

STEWART I, Khakwani A, Hubbard RB, Beckett P, et al
Are working practices of lung cancer nurse specialists associated with variation in peoples' receipt of anticancer therapy?
Lung Cancer. 2018;123:160-165.
PubMed Abstract available

CARDINALE D, Cosentino N, Moltrasio M, Sandri MT, et al
Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide.
Lung Cancer. 2018;123:155-159.
PubMed Abstract available

POMPILI C, Koller M, Velikova G, Franks K, et al
EORTC QLQ-C30 summary score reliably detects changes in QoL three months after anatomic lung resection for Non-Small Cell Lung Cancer (NSCLC).
Lung Cancer. 2018;123:149-154.
PubMed Abstract available

CHO BC, Dy GK, Govindan R, Kim DW, et al
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
Lung Cancer. 2018;123:14-21.
PubMed Abstract available

FINKLE JH, Penney BC, Pu Y
An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
Lung Cancer. 2018;123:136-141.
PubMed Abstract available

LI Z, Maeda D, Yoshida M, Umakoshi M, et al
The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
Lung Cancer. 2018;123:127-135.
PubMed Abstract available

KOUL R, Rathod S, Dubey A, Bashir B, et al
Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.
Lung Cancer. 2018;123:116-120.
PubMed Abstract available

DE JONG EEC, Hendriks LEL, van Elmpt W, Gietema HA, et al
What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.
Lung Cancer. 2018;123:112-115.
PubMed Abstract available

HASHIMOTO K, Daddi N, Giuliani M, Hope A, et al
The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer.
Lung Cancer. 2018;123:1-6.
PubMed Abstract available

August 2018

DICKHOFF C, Dahele M
In Regard to Robinson et al: Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
Lung Cancer. 2018 Aug 16. pii: S0169-5002(18)30527.
PubMed

CHOUAID C, Danson S, Andreas S, Siakpere O, et al
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.
Lung Cancer. 2018 Aug 10. pii: S0169-5002(18)30503.
PubMed Abstract available

LEE YG, Lee JH, Kim SH, Kim YJ, et al
Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
Lung Cancer. 2018;122:88-93.
PubMed Abstract available

HO JC, Leung CC
Management of co-existent tuberculosis and lung cancer.
Lung Cancer. 2018;122:83-87.
PubMed Abstract available

GUIBERT N, Tsukada H, Hwang DH, Chambers E, et al
Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.
Lung Cancer. 2018;122:72-75.
PubMed Abstract available

CHAFT JE, Dagogo-Jack I, Santini FC, Eng J, et al
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
Lung Cancer. 2018;122:67-71.
PubMed Abstract available

DENG W, Xu T, Wang Y, Xu Y, et al
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
Lung Cancer. 2018;122:60-66.
PubMed Abstract available

OSUOHA CA, Callahan KE, Ponce CP, Pinheiro PS, et al
Disparities in lung cancer survival and receipt of surgical treatment.
Lung Cancer. 2018;122:54-59.
PubMed Abstract available

SI X, Zhang L, Wang H, Zhang X, et al
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Lung Cancer. 2018;122:32-37.
PubMed Abstract available

TRIPHURIDET N, Vidhyarkorn S, Worakitsitisatorn A, Sricharunrat T, et al
Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes.
Lung Cancer. 2018;122:243-248.
PubMed Abstract available

LEE JS, Lee KH, Cho EK, Kim DW, et al
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
Lung Cancer. 2018;122:234-242.
PubMed Abstract available

ZAHEDI A, Phandthong R, Chaili A, Remark G, et al
Epithelial-to-mesenchymal transition of A549 lung cancer cells exposed to electronic cigarettes.
Lung Cancer. 2018;122:224-233.
PubMed Abstract available

AHMED T, Vial MR, Ost D, Stewart J, et al
Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.
Lung Cancer. 2018;122:220-223.
PubMed Abstract available

TAKAHASHI N, Tsuji K, Tamiya H, Shinohara T, et al
Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
Lung Cancer. 2018;122:22-24.
PubMed Abstract available

GOYAL G, Kommalapati A, Bartley AC, Gunderson TM, et al
Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer.
Lung Cancer. 2018;122:214-219.
PubMed Abstract available

ROBINSON LA, Tanvetyanon T, Grubbs D, Antonia S, et al
Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.
Lung Cancer. 2018;122:206-213.
PubMed Abstract available

IZUMI H, Yamasaki A, Takeda K, Kodani M, et al
Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Lung Cancer. 2018;122:200-205.
PubMed Abstract available

MATYS T, Drury R, David S, Rassl DM, et al
Routine preoperative brain CT in resectable non-small cell lung cancer - Ten years experience from a tertiary UK thoracic center.
Lung Cancer. 2018;122:195-199.
PubMed Abstract available

YAP S, Goldsbury D, Yap ML, Yuill S, et al
Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study.
Lung Cancer. 2018;122:171-179.
PubMed Abstract available

BRUSTUGUN OT, Gronberg BH, Fjellbirkeland L, Helbekkmo N, et al
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.
Lung Cancer. 2018;122:138-145.
PubMed Abstract available

MILLARES L, Barreiro E, Cortes R, Martinez-Romero A, et al
Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
Lung Cancer. 2018;122:124-130.
PubMed Abstract available

INOUE T, Katoh N, Ito YM, Kimura T, et al
Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study.
Lung Cancer. 2018;122:107-112.
PubMed Abstract available

SEBASTIAN M, Ryden A, Walding A, Papadimitrakopoulou V, et al
Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer.
Lung Cancer. 2018;122:100-106.
PubMed Abstract available

ZHAO B, Zhang W, Yu D, Xu J, et al
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Lung Cancer. 2018;122:10-21.
PubMed Abstract available

WANG H, Zhang L, Hu P, Zheng X, et al
Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.
Lung Cancer. 2018;122:1-6.
PubMed Abstract available

July 2018

TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
Corrigendum to "Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden" [Lung Cancer 120 (June) (2018) 75-81].
Lung Cancer. 2018 Jul 13. pii: S0169-5002(18)30468.
PubMed

VERONESI G, Zulueta JJ, Maisonneuve P, Henschke C, et al
At last we can go ahead with low-dose CT screening for lung cancer in Europe.
Lung Cancer. 2018 Jul 10. pii: S0169-5002(18)30470.
PubMed

KUIJPERS CCHJ, Hendriks LEL, Derks JL, Dingemans AC, et al
Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.
Lung Cancer. 2018;121:76-81.
PubMed Abstract available

TOMONAGA Y, Ten Haaf K, Frauenfelder T, Kohler M, et al
Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
Lung Cancer. 2018;121:61-69.
PubMed Abstract available

XIE F, Zhang Y, Mao X, Zheng X, et al
Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naive advanced non-squamous non-small cell lung cancer patients.
Lung Cancer. 2018;121:54-60.
PubMed Abstract available

NIE K, Zhang Z, Zhang C, Geng C, et al
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
Lung Cancer. 2018;121:5-11.
PubMed Abstract available

KOBAYASHI H, Naito T, Omae K, Omori S, et al
ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease.
Lung Cancer. 2018;121:48-53.
PubMed Abstract available

NISHIO M, Nakagawa K, Mitsudomi T, Yamamoto N, et al
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Lung Cancer. 2018;121:37-40.
PubMed Abstract available

TOPKAN E, Selek U, Ozdemir Y, Yildirim BA, et al
Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
Lung Cancer. 2018;121:30-36.
PubMed Abstract available

YANG M, Tong X, Xu X, Zheng E, et al
Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex.
Lung Cancer. 2018;121:1-4.
PubMed Abstract available

June 2018

ANDREAS S, Chouaid C, Danson S, Siakpere O, et al
Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Lung Cancer. 2018 Jun 9. pii: S0169-5002(18)30416.
PubMed Abstract available

KIMURA S, Harada T, Ijichi K, Tanaka K, et al
Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.
Lung Cancer. 2018;120:98-107.
PubMed Abstract available

LIMWATTANANON C, Limwattananon S, Waleekhachonloet O, Rattanachotphanit T, et al
Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
Lung Cancer. 2018;120:91-97.
PubMed Abstract available

ROBIN TP, Jones BL, Amini A, Koshy M, et al
Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
Lung Cancer. 2018;120:88-90.
PubMed Abstract available

TENDLER S, Grozman V, Lewensohn R, Tsakonas G, et al
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden.
Lung Cancer. 2018;120:75-81.
PubMed Abstract available

RECK M, Garassino MC, Imbimbo M, Shepherd FA, et al
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Lung Cancer. 2018;120:62-69.
PubMed Abstract available

LEE CC, Zheng H, Soon YY, Foo LL, et al
Association between radiation heart dosimetric parameters, myocardial infarct and overall survival in stage 3 non-small cell lung cancer treated with definitive thoracic radiotherapy.
Lung Cancer. 2018;120:54-59.
PubMed Abstract available

FORSTER M, Hackshaw A, De Pas T, Cobo M, et al
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Lung Cancer. 2018;120:27-33.
PubMed Abstract available

BRADBURY PA, Morris DG, Nicholas G, Tu D, et al
Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.
Lung Cancer. 2018;120:142-148.
PubMed Abstract available

MAYMANI H, Hess K, Groisberg R, Hong DS, et al
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Lung Cancer. 2018;120:137-141.
PubMed Abstract available

DU M, Thompson J, Fisher H, Zhang P, et al
Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Lung Cancer. 2018;120:113-121.
PubMed Abstract available

GUIBERT N, Delaunay M, Lusque A, Boubekeur N, et al
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Lung Cancer. 2018;120:108-112.
PubMed Abstract available

REITER MJ, Nemesure A, Madu E, Reagan L, et al
Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program.
Lung Cancer. 2018;120:1-6.
PubMed Abstract available

May 2018

BRAILLON A
Second-line therapy and advanced non-small cell lung cancer: What about smoking?
Lung Cancer. 2018 May 21. pii: S0169-5002(18)30382.
PubMed

HSIEH FS, Hung MH, Wang CY, Chen YL, et al
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].
Lung Cancer. 2018 May 3. pii: S0169-5002(18)30350.
PubMed

D'SILVA A, Gardiner PA, Boyle T, Bebb DG, et al
Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.
Lung Cancer. 2018;119:78-84.
PubMed Abstract available

RAEZ LE, Cardona AF, Santos ES, Catoe H, et al
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.
Lung Cancer. 2018;119:7-13.
PubMed Abstract available

YANG SM, Chen LW, Wang HJ, Chen LR, et al
Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification.
Lung Cancer. 2018;119:56-63.
PubMed Abstract available

CHRISTOPOULOS P, Schneider MA, Bozorgmehr F, Kuon J, et al
Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
Lung Cancer. 2018;119:48-55.
PubMed Abstract available

MODING EJ, Diehn M, Wakelee HA
Circulating tumor DNA testing in advanced non-small cell lung cancer.
Lung Cancer. 2018;119:42-47.
PubMed Abstract available

FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Lung Cancer. 2018;119:14-20.
PubMed Abstract available

BORGHAEI H, Yim YM, Guerin A, Pivneva I, et al
Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Lung Cancer. 2018;119:112-119.
PubMed Abstract available

BURUDPAKDEE C, Wong W, Seetasith A, Corvino FA, et al
Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
Lung Cancer. 2018;119:103-111.
PubMed Abstract available

KANG YK, Song YS, Cho S, Jheon S, et al
Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
Lung Cancer. 2018;119:1-6.
PubMed Abstract available

April 2018

TSAO MS, Yoon JY
The eighth TNM classification for lung cancer-What is next?
Lung Cancer. 2018 Apr 25. pii: S0169-5002(18)30346.
PubMed

YEN CC, Su HC, Chu CY, Lai SJ, et al
Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
Lung Cancer. 2018 Apr 17. pii: S0169-5002(18)30342.
PubMed

LIAO WY, Ho CC, Tsai TH, Chen KY, et al
Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Lung Cancer. 2018;118:90-96.
PubMed Abstract available

HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
Lung Cancer. 2018;118:6-12.
PubMed Abstract available

SONG Z, Cheng G, Xu C, Wang W, et al
Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Lung Cancer. 2018;118:57-61.
PubMed Abstract available

LEE JW, Choi JS, Lyu J, Lee SM, et al
Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
Lung Cancer. 2018;118:41-47.
PubMed Abstract available

BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
Lung Cancer. 2018;118:20-26.
PubMed Abstract available

HELFRICH BA, Gao D, Bunn PA Jr
Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
Lung Cancer. 2018;118:148-154.
PubMed Abstract available

HUDSON A, Chan C, Woolf D, McWilliam A, et al
Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
Lung Cancer. 2018;118:139-147.
PubMed Abstract available

SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
Lung Cancer. 2018;118:134-138.
PubMed Abstract available

IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
Lung Cancer. 2018;118:13-19.
PubMed Abstract available

COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
Lung Cancer. 2018;118:119-127.
PubMed Abstract available

FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
Lung Cancer. 2018;118:111-118.
PubMed Abstract available

LIU Y, Li Y, Ou Q, Wu X, et al
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Lung Cancer. 2018;118:1-5.
PubMed Abstract available

March 2018

HSIEH FS, Hung MH, Wang CY, Chen YL, et al
Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
PubMed

LI J, Wang Z, Groen HJM, Zhao J, et al
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
PubMed

GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Lung Cancer. 2018;117:44-49.
PubMed Abstract available

SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
Lung Cancer. 2018;117:38-43.
PubMed Abstract available

SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Lung Cancer. 2018;117:32-37.
PubMed Abstract available

ZHANG B, Xu J, Zhang X, Gu P, et al
Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Lung Cancer. 2018;117:27-31.
PubMed Abstract available

YANG W, Qian F, Teng J, Wang H, et al
Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
Lung Cancer. 2018;117:20-26.
PubMed Abstract available

OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
Lung Cancer. 2018;117:14-19.
PubMed Abstract available

ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
Lung Cancer. 2018;117:1-6.
PubMed Abstract available

PARK BJ, Cho JH, Lee JH, Shin S, et al
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
Lung Cancer. 2018;117:7-13.
PubMed Abstract available

February 2018

ODA K, Kato K, Nakamura M, Jotatsu T, et al
Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
PubMed

BARUA S, Fang P, Sharma A, Fujimoto J, et al
Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
Lung Cancer. 2018 Feb 3. pii: S0169-5002(18)30236.
PubMed Abstract available

VANDERLAAN PA, Rangachari D, Majid A, Parikh MS, et al
Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
Lung Cancer. 2018;116:90-95.
PubMed Abstract available

CHENG CC, Chou KF, Wu CW, Su NW, et al
EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
Lung Cancer. 2018;116:80-89.
PubMed Abstract available

ARAN V, Masson Domingues P, Carvalho de Macedo F, Moreira de Sousa CA, et al
A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
Lung Cancer. 2018;116:7-14.
PubMed Abstract available

GAUVAIN C, Vauleon E, Chouaid C, Lerhun E, et al
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
Lung Cancer. 2018;116:62-66.
PubMed Abstract available

DRIESSEN EJM, Schulkes KJG, Dingemans AC, van Loon JGM, et al
Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
Lung Cancer. 2018;116:55-61.
PubMed Abstract available

CUI S, Cheng Z, Qin W, Jiang L, et al
Exosomes as a liquid biopsy for lung cancer.
Lung Cancer. 2018;116:46-54.
PubMed Abstract available

PARK KS, Moon YW, Raffeld M, Lee DH, et al
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
Lung Cancer. 2018;116:38-45.
PubMed Abstract available

ARNEY J, Helm A, Crook T, Braun UK, et al
Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
Lung Cancer. 2018;116:25-29.
PubMed Abstract available

MCLEER-FLORIN A, Duruisseaux M, Pinsolle J, Dubourd S, et al
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
Lung Cancer. 2018;116:15-24.
PubMed Abstract available

REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].
Lung Cancer. 2018 Feb 1. pii: S0169-5002(17)30564.
PubMed

PAAJANEN J, Laaksonen S, Ilonen I, Wolff H, et al
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Lung Cancer. 2018;116:73-79.
PubMed Abstract available

QIN BD, Jiao XD, Zang YS
Primary pulmonary leiomyosarcoma: A population-based study.
Lung Cancer. 2018;116:67-72.
PubMed Abstract available

ZHOU F, Hou L, Ding T, Song Q, et al
Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
Lung Cancer. 2018;116:30-37.
PubMed Abstract available

TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Lung Cancer. 2018;116:1-6.
PubMed Abstract available

CHEN Y, Chen B, Zhu X, Zhong J, et al
A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
Lung Cancer. 2018;116:96-98.
PubMed

January 2018

GOROSPE L, Arrieta P, Ajuria-Illarramendi O, Barbolla-Diaz I, et al
Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer.
Lung Cancer. 2018 Jan 17. pii: S0169-5002(18)30018.
PubMed

KHAN SA, Pruitt SL, Xuan L, Makris U, et al
How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
Lung Cancer. 2018;115:97-102.
PubMed Abstract available

LEE J, Kim HK, Park BJ, Cho JH, et al
Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
Lung Cancer. 2018;115:89-96.
PubMed Abstract available

TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Lung Cancer. 2018;115:84-88.
PubMed Abstract available

YANG CJ, Gu L, Shah SA, Yerokun BA, et al
Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
Lung Cancer. 2018;115:75-83.
PubMed Abstract available

SATO K, Akamatsu H, Murakami E, Sasaki S, et al
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Lung Cancer. 2018;115:71-74.
PubMed Abstract available

HUANG HC, Su WJ, Chiang CL, Feng JY, et al
The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
Lung Cancer. 2018;115:64-70.
PubMed Abstract available

TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
Lung Cancer. 2018;115:49-55.
PubMed Abstract available

THAWANI R, McLane M, Beig N, Ghose S, et al
Radiomics and radiogenomics in lung cancer: A review for the clinician.
Lung Cancer. 2018;115:34-41.
PubMed Abstract available

ISAKA M, Kojima H, Takahashi S, Omae K, et al
Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
Lung Cancer. 2018;115:28-33.
PubMed Abstract available

EVISON M, Edwards T, Balata H, Tempowski A, et al
Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
Lung Cancer. 2018;115:127-130.
PubMed Abstract available

SOO RA, Lim SM, Syn NL, Teng R, et al
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Lung Cancer. 2018;115:12-20.
PubMed Abstract available

TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Lung Cancer. 2018;115:116-120.
PubMed Abstract available

LIU X, Jiang T, Li W, Li X, et al
Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
Lung Cancer. 2018;115:109-115.
PubMed Abstract available

NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
Lung Cancer. 2018;115:103-108.
PubMed Abstract available

NAKAMURA H, Ichikawa T, Nakasone S, Miyoshi T, et al
Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Lung Cancer. 2018;115:56-63.
PubMed Abstract available

JIANG J, Wu X, Tong X, Wei W, et al
GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Lung Cancer. 2018;115:5-11.
PubMed Abstract available

MIURA Y, Kaira K, Sakurai R, Sunaga N, et al
High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
Lung Cancer. 2018;115:42-48.
PubMed Abstract available

MINARI R, Bordi P, Del Re M, Facchinetti F, et al
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
Lung Cancer. 2018;115:21-27.
PubMed Abstract available

GALLI G, Corrao G, Imbimbo M, Proto C, et al
Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
Lung Cancer. 2018;115:135-142.
PubMed Abstract available

ZHU YC, Wang WX, Xu CW, Song ZB, et al
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
Lung Cancer. 2018;115:131-134.
PubMed Abstract available

ZHANG L, Belani CP, Zhang PH, Wang X, et al
Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.
Lung Cancer. 2018;115:121-126.
PubMed Abstract available

HORNE ZD, Richman AH, Dohopolski MJ, Clump DA, et al
Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
Lung Cancer. 2018;115:1-4.
PubMed Abstract available

December 2017

LIU E, Guha A, Jia K, Ayers AM, et al
Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
PubMed

VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
PubMed

GROSSI F, Genova C, Rijavec E, Barletta G, et al
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Lung Cancer. 2017 Dec 13. pii: S0169-5002(17)30614.
PubMed Abstract available

TU HY, Ke EE, Yang JJ, Sun YL, et al
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Lung Cancer. 2017;114:96-102.
PubMed Abstract available

TIAN HX, Zhang XC, Yang JJ, Guo WB, et al
Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
Lung Cancer. 2017;114:90-95.
PubMed Abstract available

SHEN J, Ye Y, Chang DW, Huang M, et al
Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Lung Cancer. 2017;114:70-78.
PubMed Abstract available

CHALMERS A, Jensen L, Akerley W
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
Lung Cancer. 2017;114:68-69.
PubMed Abstract available

ZHU Y, Li T, Chen G, Yan G, et al
Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p.
Lung Cancer. 2017;114:6-11.
PubMed Abstract available

KEUSTERS WR, de Weger VA, Hovels A, Schellens JHM, et al
Changing costs of metastatic non small cell lung cancer in the Netherlands.
Lung Cancer. 2017;114:56-61.
PubMed Abstract available

VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Lung Cancer. 2017;114:44-49.
PubMed Abstract available

WANG X, Leader JK, Wang R, Wilson D, et al
Vasculature surrounding a nodule: A novel lung cancer biomarker.
Lung Cancer. 2017;114:38-43.
PubMed Abstract available

ZANON M, Pacini GS, de Souza VVS, Marchiori E, et al
Early detection of lung cancer using ultra-low-dose computed tomography in coronary CT angiography scans among patients with suspected coronary heart disease.
Lung Cancer. 2017;114:1-5.
PubMed Abstract available

HAN L, Lee CK, Pang H, Chan HT, et al
Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
Lung Cancer. 2017;114:79-89.
PubMed Abstract available

YAMAUCHI Y, Safi S, Muley T, Warth A, et al
C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
Lung Cancer. 2017;114:62-67.
PubMed Abstract available

KUIJVENHOVEN JC, Crombag L, Breen DP, van den Berk I, et al
Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients.
Lung Cancer. 2017;114:50-55.
PubMed Abstract available

WANG L, Guo Q, Yu W, Qiao L, et al
Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
Lung Cancer. 2017;114:31-37.
PubMed Abstract available

MATSUMURA Y, Suzuki H, Ohira T, Shiono S, et al
Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
Lung Cancer. 2017;114:23-30.
PubMed Abstract available

FOY V, Schenk MW, Baker K, Gomes F, et al
Targeting DNA damage in SCLC.
Lung Cancer. 2017;114:12-22.
PubMed Abstract available

November 2017

DUDNIK E, Moskovitz M, Daher S, Shamai S, et al
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
Lung Cancer. 2017 Nov 23. pii: S0169-5002(17)30582.
PubMed Abstract available

SCHOUTEN RD, Muller M, de Gooijer CJ, Baas P, et al
Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
Lung Cancer. 2017 Nov 17. pii: S0169-5002(17)30569.
PubMed

GOROSPE L, Garcia-Latorre R, Ajuria-Illarramendi O, Arrieta P, et al
Lipoid pneumonia mimicking multifocal lung cancer in a patient with a remote laryngectomy and a recently diagnosed lung cancer: PET/CT findings.
Lung Cancer. 2017 Nov 7. pii: S0169-5002(17)30560.
PubMed

GOROSPE L, Sanchez-Monforte JC, Cabanas-Montero J, Arrieta P, et al
Incidental retroperitoneal malignant solitary fibrous tumor detected at lung cancer screening with low-dose thoracic CT.
Lung Cancer. 2017 Nov 6. pii: S0169-5002(17)30561.
PubMed

AHMED Z, Grover P, Kennedy KF, Masood A, et al
Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis.
Lung Cancer. 2017;113:85-87.
PubMed

SPIGEL DR, Rubin MS, Gian VG, Shipley DL, et al
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
Lung Cancer. 2017;113:79-84.
PubMed Abstract available

KAWANO Y, Iwama E, Tsuchihashi K, Shibahara D, et al
CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
Lung Cancer. 2017;113:72-78.
PubMed Abstract available

KATO T, Jin CS, Ujiie H, Lee D, et al
Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
Lung Cancer. 2017;113:59-68.
PubMed Abstract available

HORN L, Gettinger S, Camidge DR, Smit EF, et al
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Lung Cancer. 2017;113:51-58.
PubMed Abstract available

HEUVELMANS MA, Walter JE, Peters RB, Bock GH, et al
Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
Lung Cancer. 2017;113:45-50.
PubMed Abstract available

HOCHMAIR MJ, Schwab S, Burghuber OC, Krenbek D, et al
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
Lung Cancer. 2017;113:4-6.
PubMed Abstract available

CORRALES-RODRIGUEZ L, Arrieta O, Mas L, Baez-Saldana R, et al
An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
Lung Cancer. 2017;113:30-36.
PubMed Abstract available

LIU C, Cui H, Gu D, Zhang M, et al
Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.
Lung Cancer. 2017;113:18-29.
PubMed Abstract available

BOUAZZA YB, Chiairi I, El Kharbouchi O, De Backer L, et al
Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review.
Lung Cancer. 2017;113:140-151.
PubMed Abstract available

SANTONI-RUGIU E, Grauslund M, Melchior LC, Costa JC, et al
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Lung Cancer. 2017;113:14-17.
PubMed Abstract available

ICHIKAWA T, Saruwatari K, Mimaki S, Sugano M, et al
Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
Lung Cancer. 2017;113:134-139.
PubMed Abstract available

SCHMIDT LH, Stucke-Ring J, Brand C, Schliemann C, et al
CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
Lung Cancer. 2017;113:121-127.
PubMed Abstract available

TALBOT T, Dangoor A, Shah R, Naik J, et al
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Lung Cancer. 2017;113:115-120.
PubMed Abstract available

LEE CK, Kim S, Lee JS, Lee JE, et al
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lung Cancer. 2017;113:106-114.
PubMed Abstract available

HASSAN A, Latif MT, Soo CI, Faisal AH, et al
Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods.
Lung Cancer. 2017;113:1-3.
PubMed Abstract available

October 2017

SAWA K, Koh Y, Kawaguchi T, Kambayashi S, et al
PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Lung Cancer. 2017;112:96-101.
PubMed Abstract available

SCHVARTSMAN G, Peng SA, Bis G, Lee JJ, et al
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung Cancer. 2017;112:90-95.
PubMed Abstract available

HSIEH FS, Hung MH, Wang CY, Chen YL, et al
Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
Lung Cancer. 2017;112:81-89.
PubMed Abstract available

HE Y, Rozeboom L, Rivard CJ, Ellison K, et al
MHC class II expression in lung cancer.
Lung Cancer. 2017;112:75-80.
PubMed Abstract available

ROS-MAZURCZYK M, Jelonek K, Marczyk M, Binczyk F, et al
Serum lipid profile discriminates patients with early lung cancer from healthy controls.
Lung Cancer. 2017;112:69-74.
PubMed Abstract available

FACCHINETTI F, Bluthgen MV, Tergemina-Clain G, Faivre L, et al
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Lung Cancer. 2017;112:62-68.
PubMed Abstract available

TOMIZAWA K, Shimizu S, Ohara S, Fujino T, et al
Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.
Lung Cancer. 2017;112:57-61.
PubMed Abstract available

LEFRESNE S, Olson R, Cashman R, Kostuik P, et al
Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic.
Lung Cancer. 2017;112:35-40.
PubMed Abstract available

NISHIE K, Yamamoto S, Nagata C, Koizumi T, et al
Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Lung Cancer. 2017;112:25-34.
PubMed Abstract available

KUYAMA S, Ochi N, Bessho A, Hotta K, et al
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
Lung Cancer. 2017;112:188-194.
PubMed Abstract available

RECK M, Paz-Ares L, Bidoli P, Cappuzzo F, et al
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Lung Cancer. 2017;112:181-187.
PubMed Abstract available

QIN N, Wang C, Zhu M, Lu Q, et al
Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.
Lung Cancer. 2017;112:169-175.
PubMed Abstract available

LARA JD, Brunson A, Riess JW, Kelly K, et al
Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
Lung Cancer. 2017;112:165-168.
PubMed Abstract available

VINOD SK, Chandra A, Berthelsen A, Descallar J, et al
Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
Lung Cancer. 2017;112:16-24.
PubMed Abstract available

JACOBSEN MM, Silverstein SC, Quinn M, Waterston LB, et al
Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review.
Lung Cancer. 2017;112:156-164.
PubMed Abstract available

EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study.
Lung Cancer. 2017;112:140-155.
PubMed Abstract available

KWINT M, Walraven I, Burgers S, Hartemink K, et al
Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
Lung Cancer. 2017;112:134-139.
PubMed Abstract available

PAZ-ARES LG, Perol M, Ciuleanu TE, Kowalyszyn RD, et al
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer. 2017;112:126-133.
PubMed Abstract available

AGGARWAL C, Wang X, Ranganathan A, Torigian D, et al
Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
Lung Cancer. 2017;112:118-125.
PubMed Abstract available

SNOECKX A, Dendooven A, Carp L, Desbuquoit D, et al
Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities.
Lung Cancer. 2017;112:109-117.
PubMed Abstract available

MEZQUITA L, Charrier M, Faivre L, Dupraz L, et al
Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
Lung Cancer. 2017;112:10-15.
PubMed Abstract available

September 2017

ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
Lung cancer in renal transplant recipients: A case-control study.
Lung Cancer. 2017;111:96-100.
PubMed Abstract available

MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
Lung Cancer. 2017;111:88-95.
PubMed Abstract available

LIM SM, Chang H, Cha YJ, Liang S, et al
Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lung Cancer. 2017;111:79-83.
PubMed Abstract available

MOON SM, Lee DG, Hwang NY, Ahn S, et al
Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
Lung Cancer. 2017;111:69-74.
PubMed Abstract available

TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
Lung Cancer. 2017;111:65-68.
PubMed Abstract available

CAPELAN M, Roda D, Geuna E, Rihawi K, et al
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Lung Cancer. 2017;111:6-11.
PubMed Abstract available

CALIFANO R, Greystoke A, Lal R, Thompson J, et al
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Lung Cancer. 2017;111:51-58.
PubMed Abstract available

SHEN L, Niu X, Jian H, Xu Y, et al
Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Lung Cancer. 2017;111:43-50.
PubMed Abstract available

MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Lung Cancer. 2017;111:38-42.
PubMed Abstract available

GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
Lung Cancer. 2017;111:30-37.
PubMed Abstract available

LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Lung Cancer. 2017;111:23-29.
PubMed Abstract available

HATA A, Katakami N, Nanjo S, Okuda C, et al
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Lung Cancer. 2017;111:182-189.
PubMed Abstract available

DIEM S, Schmid S, Krapf M, Flatz L, et al
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Lung Cancer. 2017;111:176-181.
PubMed Abstract available

SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
Lung Cancer. 2017;111:164-175.
PubMed Abstract available

RUELLE L, Bentea G, Sideris S, El Koulali M, et al
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
Lung Cancer. 2017;111:150-163.
PubMed Abstract available

WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
Lung Cancer. 2017;111:15-22.
PubMed Abstract available

YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
Lung Cancer. 2017;111:131-134.
PubMed Abstract available

GAGLIASSO M, Migliaretti G, Ardissone F
Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
Lung Cancer. 2017;111:124-130.
PubMed Abstract available

TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
Lung Cancer. 2017;111:101-107.
PubMed Abstract available

FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Lung Cancer. 2017;111:1-5.
PubMed Abstract available

August 2017

VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
PubMed Abstract available

CHENG YW, Chiou HL, Chen JT, Chou MC, et al
Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
PubMed

LIAO BC, Lin CC, Lee JH, Yang JC, et al
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Lung Cancer. 2017;110:7-13.
PubMed Abstract available

KIM EY, Kim A, Kim SK, Chang YS, et al
MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Lung Cancer. 2017;110:63-67.
PubMed Abstract available

KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
Lung Cancer. 2017;110:53-55.
PubMed Abstract available

TAO MH, Dai Q, Chen S, Freudenheim JL, et al
Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
Lung Cancer. 2017;110:42-47.
PubMed Abstract available

KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Lung Cancer. 2017;110:35-41.
PubMed Abstract available

SANDS J, Li Q, Hornberger J
Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Lung Cancer. 2017;110:19-25.
PubMed Abstract available

DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
Lung Cancer. 2017;110:14-18.
PubMed Abstract available

July 2017

LIU E, Guha A, Bertino E, Franco V, et al
Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
PubMed

SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
PubMed Abstract available

TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
PubMed

YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Lung Cancer. 2017;109:89-91.
PubMed Abstract available

WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
Lung Cancer. 2017;109:78-88.
PubMed Abstract available

LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
Lung Cancer. 2017;109:68-73.
PubMed Abstract available

ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
Lung Cancer. 2017;109:62-67.
PubMed Abstract available

FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
Lung Cancer. 2017;109:52-57.
PubMed Abstract available

GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
Lung Cancer. 2017;109:36-41.
PubMed Abstract available

ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Lung Cancer. 2017;109:28-35.
PubMed Abstract available

O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
Uncommon EGFR mutations in advanced non-small cell lung cancer.
Lung Cancer. 2017;109:137-144.
PubMed Abstract available

WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
Lung Cancer. 2017;109:117-123.
PubMed Abstract available

SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Lung Cancer. 2017;109:1-8.
PubMed Abstract available

DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
Lung Cancer. 2017;109:92-100.
PubMed Abstract available

DEARDEN S, Brown H, Jenkins S, Thress KS, et al
EGFR T790M mutation testing within the osimertinib AURA Phase I study.
Lung Cancer. 2017;109:9-13.
PubMed Abstract available

RASKIN J, Masrori P, Cant A, Snoeckx A, et al
Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
Lung Cancer. 2017;109:74-77.
PubMed Abstract available

ITO J, Fujimoto D, Nakamura A, Nagano T, et al
Aprepitant for refractory nivolumab-induced pruritus.
Lung Cancer. 2017;109:58-61.
PubMed Abstract available

YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
Lung Cancer. 2017;109:45-51.
PubMed Abstract available

UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Lung Cancer. 2017;109:42-44.
PubMed Abstract available

ZHANG L, Li S, Choi YL, Lee J, et al
Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
Lung Cancer. 2017;109:21-27.
PubMed Abstract available

BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
Lung Cancer. 2017;109:14-20.
PubMed Abstract available

HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
Lung Cancer. 2017;109:128-136.
PubMed Abstract available

ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
Lung Cancer. 2017;109:124-127.
PubMed Abstract available

ZHANG L, Li J, Hu J, Li D, et al
Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
Lung Cancer. 2017;109:109-116.
PubMed Abstract available

GADGEEL S, Goss G, Soria JC, Felip E, et al
Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
Lung Cancer. 2017;109:101-108.
PubMed Abstract available

June 2017

GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
PubMed

ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Lung Cancer. 2017;108:96-102.
PubMed Abstract available

GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
Lung Cancer. 2017;108:90-95.
PubMed Abstract available

IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Lung Cancer. 2017;108:83-89.
PubMed Abstract available

HIDAKA N, Iwama E, Kubo N, Harada T, et al
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
Lung Cancer. 2017;108:75-82.
PubMed Abstract available

GION M, Remon J, Caramella C, Soria JC, et al
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
Lung Cancer. 2017;108:72-74.
PubMed Abstract available

NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
Lung Cancer. 2017;108:66-71.
PubMed Abstract available

MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
Lung Cancer. 2017;108:62-65.
PubMed Abstract available

YU XQ, Luo Q, Kahn C, Grogan P, et al
Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
Lung Cancer. 2017;108:55-61.
PubMed Abstract available

CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
Lung Cancer. 2017;108:38-44.
PubMed Abstract available

SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
Lung Cancer. 2017;108:232-237.
PubMed Abstract available

KOSHY M, Malik R, Spiotto M, Mahmood U, et al
Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Lung Cancer. 2017;108:222-227.
PubMed Abstract available

RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
Lung Cancer. 2017;108:217-221.
PubMed Abstract available

WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Lung Cancer. 2017;108:212-216.
PubMed Abstract available

DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
Lung Cancer. 2017;108:198-204.
PubMed Abstract available

YANG SC, Lai WW, Lin CC, Su WC, et al
Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
Lung Cancer. 2017;108:183-191.
PubMed Abstract available

HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
Lung Cancer. 2017;108:173-182.
PubMed Abstract available

MORAN T, Palmero R, Provencio M, Insa A, et al
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Lung Cancer. 2017;108:154-160.
PubMed Abstract available

MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Lung Cancer. 2017;108:15-21.
PubMed Abstract available

PATEL MI, McKinley M, Cheng I, Haile R, et al
Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
Lung Cancer. 2017;108:140-149.
PubMed Abstract available

KRON F, Kostenko A, Scheffler M, Muller D, et al
Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
Lung Cancer. 2017;108:134-139.
PubMed Abstract available

KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Lung Cancer. 2017;108:126-133.
PubMed Abstract available

PATEL SH, Rimner A, Foster A, Zhang Z, et al
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Lung Cancer. 2017;108:109-114.
PubMed Abstract available

MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
Lung Cancer. 2017;108:103-108.
PubMed Abstract available

April 2017

SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
PubMed

TANAKA N, Toyooka S, Soh J, Kubo T, et al
Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
PubMed

EDWARDS T, Balata H, Foden P, Crosbie P, et al
Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
PubMed

METRO G, Tazza M, Matocci R, Chiari R, et al
Optimal management of ALK-positive NSCLC progressing on crizotinib.
Lung Cancer. 2017;106:58-66.
PubMed Abstract available

BASLER L, Kroeze SG, Guckenberger M
SBRT for oligoprogressive oncogene addicted NSCLC.
Lung Cancer. 2017;106:50-57.
PubMed Abstract available

VANDERLAAN PA, Rangachari D, Mockus SM, Spotlow V, et al
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Lung Cancer. 2017;106:17-21.
PubMed Abstract available

KWON D, Koh J, Kim S, Go H, et al
MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Lung Cancer. 2017;106:131-137.
PubMed Abstract available

HONG SW, Park NS, Noh MH, Shim JA, et al
Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Lung Cancer. 2017;106:115-124.
PubMed Abstract available

March 2017

LI H, Yang T, Ning Q, Shang D, et al
MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
PubMed Abstract available

CAPELLETTO E, Mariniello A, Novello S
Targeted therapy in small cell lung cancer: A new era?
Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
PubMed

February 2017

HIDA T, Hamasaki M, Matsumoto S, Sato A, et al
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Lung Cancer. 2017;104:98-105.
PubMed Abstract available

SAKAGUCHI H, Ishida H, Nitanda H, Yamazaki N, et al
Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
Lung Cancer. 2017;104:70-74.
PubMed Abstract available

TAKADA K, Okamoto T, Toyokawa G, Kozuma Y, et al
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Lung Cancer. 2017;104:7-15.
PubMed Abstract available

LAURIE SA, Hao D, Leighl NB, Goffin J, et al
A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
Lung Cancer. 2017;104:65-69.
PubMed Abstract available

WU YL, Saijo N, Thongprasert S, Yang JC, et al
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Lung Cancer. 2017;104:119-125.
PubMed Abstract available

January 2017

TO KK, Tong WS, Fu LW
Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
Lung Cancer. 2017;103:58-65.
PubMed Abstract available

TSIM S, Stobo DB, Alexander L, Kelly C, et al
The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
Lung Cancer. 2017;103:38-43.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: